Pharmaceuticals

New York, November 2023: According to a new research study by Global Insight Services (GIS), the Sildenafil Drug Market is expected to grow rapidly over the next 10 years to reach a value of more than US$ 4.5 billion by 2032.

Sildenafil is a PDE5 inhibitor that is used to treat erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). It improves blood flow to the penis, allowing it to attain and sustain an erection, making it an effective impotence therapy.

Request Sample Pages of this Research Report

https://www.globalinsightservices.com/request-sample/GIS26635

Global Sildenafil Drug Market: Market Drivers and Trends

Erectile dysfunction (ED) is becoming more common: Erectile dysfunction (ED) is becoming more common across the world. According to statistics, 30-40% of men have ED by the age of 40. The expanding senior population and age-related health conditions are adding to the patient pool. The large unmet demands of ED patients are projected to fuel sildenafil medication demand in the next years. With increased ED therapy awareness and acceptability, patient usage of sildenafil is anticipated to rise.

Patent expiration leads to the release of generics: The patent expiration of branded sildenafil medications such as Viagra has resulted in the release of generic equivalents by several pharmaceutical firms. The reduced cost of generics in comparison to branded counterparts is increasing their popularity. To gain market share, companies are concentrating on producing generic sildenafil formulations. The advent of generics has made ED therapy more accessible and inexpensive, propelling the sildenafil medication industry forward.

Global Sildenafil Drug Market: Market Restraints and Challenges

Side effects and safety concerns: Sildenafil use has been linked to headaches, flushing, vision abnormalities, back discomfort, and gastrointestinal difficulties. There have also been occasional reports of major side effects such as hearing and vision loss. Concerns about harmful effects restrict the widespread use of sildenafil medicines. This needs thorough monitoring and care during therapy. Providers frequently avoid providing sildenafil to patients who have specific medical issues, which impedes progress.

Social stigma connected with ED: The social stigma and humiliation associated with sexual illnesses such as erectile dysfunction sometimes deter people from seeking medical help. Many individuals are reluctant to discuss sexual issues with their doctors. The stigma reduces the number of patients who are diagnosed and treated with sildenafil. Efforts to raise knowledge and sensitize the public about ED will assist in alleviating this constraint.

Global Sildenafil Drug Market Report Findings

https://www.globalinsightservices.com/reports/sildenafil-drug-market/

The branded drugs segment is likely to hold the major share of the market in 2022

Based on drug type, the Sildenafil Drug is segmented into branded drugs, generic drugs, and over the counter drugs. The branded drugs segment is expected to dominate the market during the forecast period.

The erectile dysfunction segment is likely to hold the major share of the market in 2022

By indication, the market is classified into erectile dysfunction, pulmonary arterial hypertension, benign prostatic hyperplasia, and others. The erectile dysfunction segment dominated the market in 2022 in terms of revenue and is expected to dominate the market during the forecast period.

The hospital pharmacies segment is likely to hold the major share of the market in 2022

Based on distribution channel, the Sildenafil Drug is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. In 2022, the hospital pharmacies segment dominated the market in terms of revenue and is expected to be the same during the upcoming years.

The tablets segment is likely to hold the major share of the market in 2022

Based on dosage form, the Sildenafil Drug is segmented into tablets, oral jellies, injections, and others. The tablets segment is expected to dominate the market during the forecast period.

The North America region is accounted for the majority of market share in 2022

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America has the biggest market share in terms of Sildenafil Drug value followed by Europe North America’s market development is attributable to high ED awareness, simple availability and access to ED medications, and the presence of key companies in the area. The European market for Sildenafil Drug Market is predicted to be the second largest. The expanding elderly population, increasing frequency of chronic conditions, and the introduction of new generic ED medications are driving market expansion in Europe. During the projected period, the Asia Pacific market is likely to be the fastest-growing market for Sildenafil Drug Market. The Asia Pacific market is booming due to an increasing patient population, increased healthcare spending, and an increase in online sales of ED medications.

Have a question for our analyst

https://www.globalinsightservices.com/inquiry-before-buying/GIS26635

Competitive Landscape

The key players studied in the global Sildenafil Drug Market are Pfizer, Teva Pharmaceuticals, Aurobindo Pharma , Alembic Pharmaceuticals , Torrent Pharmaceuticals , Lupin, Reddy’s Laboratories, Zydus Cadila, Amneal Pharmaceuticals, and Hetero among others.

Global Sildenafil Drug Market: Recent Developments

• In October 2022, Hetero and Biophore formed a strategic alliance to launch Sildenafil tablets in the United States. The partnership paired Biophore’s R&D skills with Hetero’s global reach of more than 100 nations.
• In January 2022, Sildenafil pills, a generic version of Viagra, received FDA approval, expanding the company’s generics range in the US.
• In June 2021, Following FDA permission, Aurobindo Pharma introduced Sildenafil pills. In the US market, the medicine is believed to aid people suffering from erectile dysfunction.
• In April 2021, Dr. Reddy has bought Eton Pharmaceuticals ‘EM-104, a novel oral suspension formulation of Sildenafil. The acquisition broadened Dr. Reddy’s product range in the male health sector in the United States.
• In March 2020, Lupin announced the introduction of Sildenafil pills after getting FDA clearance. The product broadened the company’s portfolio in the generics market in the United States.
• January 2020, Cipla purchased Exelan’s sildenafil products used to treat pulmonary arterial hypertension (PAH) in more than 15 countries. Cipla’s worldwide respiratory product portfolio was enhanced because of the purchase.

Global Sildenafil Drug Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Sildenafil Drug Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future global Sildenafil Drug Market potential from 2022 to 2032 in terms of revenue ($ Million), and Volume (Units).
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the global Sildenafil Drug Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global Sildenafil Drug Market industry.

Global Sildenafil Drug Market Segmentation

By Drug Type

• Branded Drugs
• Generic Drugs
• Over the Counter Drugs

By Indication

• Erectile Dysfunction
• Pulmonary Arterial Hypertension
• Benign Prostatic Hyperplasia
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Dosage Form

• Tablets
• Oral Jellies
• Injections
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of the World
  • Latin America
  • Middle East
  • Africa

Key Players

• Pfizer
• Teva Pharmaceuticals
• Aurobindo Pharma
• Alembic Pharmaceuticals
• Torrent Pharmaceuticals
• Lupin
• Reddy’s Laboratories
• Zydus Cadila
• Amneal Pharmaceuticals
• Hetero

New York, November 2023: According to a new research study by Global Insight Services (GIS), the Visual Arts Therapy Market is expected to grow rapidly over the next 10 years to reach a value of more than US$ 4.3 billion by 2032.

Drawing, painting, sculpture, and other art forms are used in visual arts therapy to promote physical, mental, and emotional well-being. It is utilized to treat a variety of mental health difficulties, cognitive impairments, and chronic health conditions by providing a nonverbal avenue for expression and communication.

Request Sample Pages of this Research Report

https://www.globalinsightservices.com/request-sample/GIS26634

Global Visual Arts Therapy Market: Market Drivers and Trends

Growing incidence of Mental Health problems: A key reason driving development in the visual arts therapy market is the growing incidence of mental health problems such as anxiety, depression, Post-traumatic Stress Disorder (PTSD), drug misuse, and trauma. The World Health Organization (WHO) estimates that around 1 billion individuals worldwide suffer from a mental condition. Visual arts therapy can assist people with various mental health issues to improve their symptoms and quality of life. The growing prevalence of mental diseases and the need for effective treatments are driving up demand for arts-based therapy.

Growing Geriatric Population: The world’s growing aging population creates considerable prospects for the visual arts therapeutic sector. Older persons are more vulnerable to age-related illnesses that impair cognitive functions, such as dementia, Alzheimer’s, and other neurodegenerative disorders. In older people, visual art approaches can increase brain activity, improve motor abilities, and improve mood and cognition. The aging population’s sensitivity to mental health decline is predicted to enhance the use of art treatments.

Global Visual Arts Therapy Market: Market Restraints and Challenges

The increased in maintenance costs & design limitations are likely to hinder the growth of the worldwide Visual Arts Many insurers continue to deny coverage for art therapy treatments, and out-of-pocket expenses remain high, restricting uptake. Certain private insurance plans only cover a portion of the therapist’s services if the therapist is an approved healthcare professional. Medicare likewise restricts reimbursement for creative art treatments. A key barrier influencing market potential is a lack of comprehensive coverage mixed with high therapeutic costs.

Lack of Trained Specialists: The visual arts therapy business is facing a serious supply-side restriction due to a lack of competent therapists to fulfill rising demand. Most nations have a scarcity of recognized graduate schools and supervised clinical training opportunities. Prospective students are often put off by the hard educational requirements and high expense of art therapy master’s degrees. The scarcity of qualified art therapists is a major impediment to industry expansion.

Global Visual Arts Therapy Market Report Findings

https://www.globalinsightservices.com/reports/visual-arts-therapy-market/

The photography segment is likely to hold the major share of the market in 2022

Based on type, it is segmented into painting, music, dance, drama, photography, and others. The photography segment had the highest revenue share in 2022 and is expected to continue to dominate the market over the period.

The PTSD patients segment is likely to hold the major share of the market in 2022

Based on application, it is bifurcated into cancer patients, dementia patients, PTSD patients, physical disabilities, mental health issues, substance abuse issues, and others. The PTSD patients segment has dominated the market in 2022 and expected to expand the fastest.

The rehab centers segment is likely to hold the major share of the market in 2022

Based on end user, it is segmented into hospitals, rehab centers, nursing homes, community centers, psychiatric facilities, counseling practices, and others. The rehab centers segment is expected to be the largest segment in the Visual Arts Therapy Market in 2022.

The North America region is accounted for the majority of market share in 2022

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. In 2022, the North America region Visual Arts Therapy Market had the highest revenue share followed by Europe. North America’s market development may be ascribed to the region’s high awareness levels, developed healthcare infrastructure, and advantageous reimbursement policies. Visual arts therapy is predicted to be the second-largest market in Europe. The increase is due to the region’s growing senior population and the increased use of art therapy in hospital settings. During the projection period, Asia Pacific is predicted to be the fastest-growing market for visual arts therapy. The increase is due to rising healthcare costs and the increasing use of expressive arts therapy in the region’s schools and community organizations.

Have a question for our analyst

https://www.globalinsightservices.com/inquiry-before-buying/GIS26634

Competitive Landscape

The key players studied in the global Visual Arts Therapy Market are NeurAbilities Healthcare , Promises Healthcare , Allied Health 2U, Sensational Kids., Laura Baker Services Association , Creative Clinical Consulting LLC , Luna Psychotherapy , Early Links , American Art Therapy Association , and Vlinder Expressive Arts Therapy Gold Coast among others.

Global Visual Arts Therapy Market: Recent Developments

• In September 2023, The Graduate Art Therapy Program expanded its partnership with the Rubin Museum to provide free art therapy sessions to the public.
• In July 2023, Driscoll Children’s Hospital, a pediatric tertiary care hospital, launched the first-ever art therapy program, allowing kids to express themselves in ways that words may not always be able to.
• In July 2023, through poems and collages, students from the Dominican University of California’s MFA in Creative Writing and Ph.D. in Art Therapy departments collaborated. The two programs at the School of Liberal Arts and Education collaborated during the annual MFA Summer Residency, which was attended by 31 Dominican students.
• In October 2022, Naropa University has introduced a new online bachelor’s degree program in art therapy. Students actively participate in contemplative research, personal art making, and artist identity development in addition to a comprehensive study of the therapeutic theories required preparing for a profession as an art therapist. A critical component of this cautious approach to the new internet medium.

Global Visual Arts Therapy Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Visual Arts Therapy Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future global Visual Arts Therapy Market potential from 2022 to 2032 in terms of revenue($ Million), and Volume(Units).
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the global Visual Arts Therapy Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global Security Robots industry.

Global Visual Arts Therapy Market Segmentation

By Type

• Painting
• Music
• Dance
• Drama
• Photography
• Others

By Application

• Cancer Patients
• Dementia Patients
• PTSD Patients
• Physical Disabilities
• Mental Health Issues
• Substance Abuse Issues
• Others

By End User

• Hospitals
• Rehab Centers
• Nursing Homes
• Community Centers
• Psychiatric Facilities
• Counseling Practices
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of the World
  • Latin America
  • Middle East
  • Africa

Key Players

• NeurAbilities Healthcare
• Promises Healthcare
• Allied Health 2U
• Sensational Kids.
• Laura Baker Services Association
• Creative Clinical Consulting LLC
• Luna Psychotherapy
• Early Links
• American Art Therapy Association
• Vlinder Expressive Arts Therapy Gold Coast

New York, September 2023: According to a new research study by Global Insight Services (GIS), the Animal Model Market is expected to grow rapidly over the next 10 years to reach a value of more than US$ 3.6 billion by 2032.

Non-human organisms, usually animals, are employed in scientific research to examine biological processes, discover disease causes, create new therapies, and gain knowledge about human health and physiology. Animal models are important in many domains, including medicine, pharmacology, genetics, and toxicity. They enable researchers to comprehend complicated biological systems, test ideas, and make forecasts before proceeding to human trials.

Request Sample Pages of this Research Report

https://www.globalinsightservices.com/request-sample/GIS25738/

Animal Model Market: Market Drivers and Trends

Rise in the usage of the animal models in virology is driving the market expansion. Animal models, including mice, rats, guinea pigs, and nonhuman primates, are critical in investigating the pathophysiology, transmission, and potential therapies for a variety of viral infections and infectious illnesses. These models provide a crucial platform for researchers to better understand the intricate mechanisms of viral replication, host immune responses, and disease development. Animal models have been found to be invaluable tools in virology research, enabling scientists to simulate human illnesses and evaluate the efficiency of antiviral medicines and vaccinations. In the instance of the COVID-19 pandemic, for example, animal models were critical in comprehending the SARS-CoV-2 virus and assessing prospective treatment strategies. Researchers to explore viral entrance, replicating, and dissemination, as well as to evaluate vaccine candidates and antiviral medicines utilized animal models. These studies shed light on the virus’s behaviour and aided in the development of efficient preventative and treatment measures.

Additionally, increase in the CRISPR technology is going to boost the market growth in the coming years. CRISPR allows scientists to modify individual genes in animals with remarkable accuracy, resulting in more precise disease models. Scientists can imitate the genetic abnormalities found in patients by introducing particular mutations linked with human illnesses into animal genomes, allowing for a deeper understanding of disease processes and the evaluation of prospective therapeutic approaches. CRISPR, for example, has been used to investigate cancer, based on a 2022 report by the National Library of Medicine, since the approach offers various new methods to mimic the illness. This involves the creation of pre-clinical cancer models in which CRISPR is used to produce mutations found in human cancer. As a result, rare mutations may be examined in a physiologically appropriate context, and CRISPR technology has sped up the development of these models. CRISPR technology developers Emmanuelle Charpentier and Jennifer Doudna were awarded the Nobel Prize in 2020. These drivers are likely to propel market expansion.

Animal Model Market: Market Restraints and Challenges

To ensure the ethical and appropriate application of animals in scientific research, strict regulatory criteria for animal model utilization are in place. To protect animal welfare, a structure of strong regulations and rigid norms exists. These restrictions are extensive and differ from one country to the next. Typically, regulatory requirements demand that researchers establish the scientific need and possible benefits of utilizing animal models. Institutional animal care and use committees (IACUCs) or equivalent regulatory agencies conduct ethical reviews of research proposals involving animal testing. These committees evaluate the proposed studies’ rationale, design, and welfare issues. Such severe and changeable laws may impede the employing of animal models in scientific research, stifling corporate growth.

Animal Model Market Report Findings

https://www.globalinsightservices.com/reports/animal-model-market/

The mice segment is likely to hold the major share of the market in 2022

Based on animal type, the Animal Model Market is segmented into rat, mice, guinea pigs, rabbits, and others. The mice segment is expected to dominate the market during the forecast period. Increased investment and technical improvement in mouse model technologies are expected to fuel market expansion. Furthermore, the growing implications of mouse clinical trials for further predicted results, as well as the increasing desire for personalized therapy, are driving up demand for mice models. For example, in March 2023, National Institutes of Health researchers investigated an improved genetic animal model of Down syndrome. The unique mouse model provided prospective treatment possibilities for the illness.

The cancer segment is likely to hold the major share of the market in 2022

By application, the market is classified into cancer, immunological disease, infectious disease, and others. The cancer segment dominated the market in 2022 in terms of revenue and is expected to dominate the market during the forecast period. The market is expected to rise due to factors such as the translational importance of animal models in cancer research, the growing trend of precision oncology, and developments in tumor modeling methodologies. These models are used to assess the safety and effectiveness of anti-cancer treatments in clinical trials and preclinical testing. Furthermore, animal models assist researchers in testing the therapeutic index, bioavailability, and pharmacokinetic features of anti-cancer medicines prior to moving on with human clinical trials. Charles River Laboratories and Creative Biolabs are two firms that provide models for cancer research and treatment development.

The pharma and biotech companies segment is likely to hold the major share of the market in 2022

Based on end-user, the Animal Model Market is segmented into pharmaceutical & biotechnology companies, academic research institute, and contract research organization. In 2022, the pharma and biotech companies segment dominated the market in terms of revenue and is expected to be the same during the upcoming years. Companies’ increased attempts to create innovative treatment regimens are expected to boost the segment’s growth. Additionally, pharmaceutical firms’ increased medication discovery and development operations are contributing to category expansion. Furthermore, a large number of research-driven pharmaceutical businesses and their numerous activities are expected to boost market expansion.

The North America region is accounted for the majority of market share in 2022

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America has the biggest market share in terms of Animal Model Market value followed by Asia Pacific. The presence of significant companies and many strategic efforts by them are attributed to the region’s growth. Furthermore, expanding biomedical research and clinical trial spending are driving regional market expansion. Furthermore, advances in genetic modification and the increasing use of animal-based models for drug profiling and characterization are projected to open up new opportunities for market expansion.

Have a question for our analyst

https://www.globalinsightservices.com/inquiry-before-buying/GIS25738/

Competitive Landscape

The key players studied in the Animal Model Market are The Jackson Laboratory, Charles River Laboratories, Crown Bioscience Inc., Janvier Labs, Hera Biolabs, Taconic Biosciences, Genoway S.A., Inotiv, Inc., Ozgene Pty Ltd., and BioSpherix, Ltd. among others.

Animal Model Market: Recent Developments

• In January 2023, Charles River Laboratories has announced the addition of two additional NCG mice strains to their triple-immunodeficient mouse model portfolio, which are best suited for investigations in cancer, immunology, and infectious diseases.
• In November 2022, Charles River Laboratories stated that it has inked a deal with Hera BioLabs to breed, distribute, market, and sell the SRG rat for use by the global preclinical research community.
• In September 2022, Genoway S.A. and Sigma-Aldrich Co LLC established a new framework for their 2018 CRISPR/Cas9 strategic collaboration. GenOway will continue to spearhead the commercialization of Sigma-Aldrich’s CRISPR patent property in rodent species.
• In June 2021, Genoway S.A. has announced a non-exclusive licence arrangement with ERS Genomics Limited. The arrangement gives GenOway access to ERS Genomics’ CRISPR/Cas9 patent portfolio in the past and in the future.
• In December 2020, Genoway S.A. has established a strategic collaboration with Cyagen to commercialise high-quality preclinical humanised immune checkpoint and immunodeficient BRGSF mice models to charity and for-profit organisations in Asia-Pacific beginning in 2020.

Animal Model Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Animal Model Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future global Animal Model Market potential from 2022 to 2032 in terms of revenue ($ Million) and Volume (Units).
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the global Animal Model Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global Animal Model Market industry.

Animal Model Market Segmentation

By Animal Type

• Rat
• Mice
• Guinea pigs
• Rabbits
• Others

By Application

• Cancer
• Immunological Disease
• Infectious Disease
• Others

By End-User

• Pharmaceutical & Biotechnology Companies
• Academic Research Institute
• Contract Research Organization

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • The U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Netherlands
  • Sweden
  • Switzerland
  • Denmark
  • Finland
  • Russia
  • Rest of Europe
• The Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Singapore
  • Indonesia
  • Taiwan
  • Malaysia
  • Rest of Asia-Pacific
• Rest of the World
  • Latin America
  • The Middle East
  • Africa

Key Players

• The Jackson Laboratory
• Charles River Laboratories
• Crown Bioscience Inc.
• Janvier Labs
• Hera Biolabs
• Taconic Biosciences
• Genoway S.A.
• Inotiv, Inc.
• Ozgene Pty Ltd.
• BioSpherix, Ltd.

Peptide Synthesis Market to Reach US$ 4.2 bn by 2032, driven by steep rise in the adoption of peptides in the pharmaceutical and consumer healthcare industries: Global Insight Services

New York, July 2023: According to a new research study by Global Insight Services (GIS), the global Peptide Synthesis Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 4.2 bn by 2032.

Peptides are a unique class of highly active and specific pharmaceutical compounds, molecularly poised between small molecules and proteins, yet biochemically and therapeutically diverse from both. The advantages of peptides, such as relative ease of synthesis, ready availability, and low toxicity, increased their applications in the pharmaceutical, nutritional, and cosmetic industries, resulting in high demand for rapid advancements in the technologies to enhance their synthesis..

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS20547/

Peptide Synthesis Market: Key Trends and Drivers

The market for peptides has experienced significant growth due to their widespread adoption in the pharmaceutical and consumer healthcare industries. Peptides are being increasingly utilized in the treatment of various lifestyle disorders, including cancers, diabetes, and obesity. The rising prevalence of these metabolic and lifestyle disorders has created a favorable environment for the application of peptide therapeutics in the fields of oncology and metabolic disorders. According to data published by the International Diabetes Federation in 2021, there were 537 million adults (20-79 years) globally living with diabetes, which accounted for approximately 1 in 10 individuals. Additionally, 541 million adults were identified as having Impaired Glucose Tolerance (IGT), putting them at a high risk of developing type 2 diabetes. Peptide therapies like Glucagon-like peptide-1amide have gained popularity in pancreatic therapy as they stimulate insulin secretion postprandially. Consequently, the increasing number of diabetic patients is expected to drive the demand for peptide drugs and contribute to market growth in the foreseeable future.

The peptide synthesis market has also witnessed significant expansion due to increased research activities, novel product approvals, and enhanced funding for research and development. Furthermore, advancements in peptide synthesizers have provided additional advantages, further fueling market growth. An example of recent progress in this field is ISSAR Pharma’s announcement in April 2021 regarding the licensing of their peptide-based New Chemical Entities (NCEs), which have reached the pre-investigational new drug (IND) filing stage and obtained a United States patent. These notable developments in peptide drugs are expected to create a surge in market demand and drive the overall growth of the industry.

Peptide Synthesis Market: Restraints & Challenges

The peptide synthesis market faces several restraints that can hinder its growth and development. Firstly, the high cost of peptide synthesis, including equipment, reagents, and skilled labor, presents a significant barrier for entry and limits the accessibility of peptide synthesis technologies. Additionally, the complexity and time-consuming nature of peptide synthesis processes pose challenges in terms of scalability and efficient production, limiting the ability to meet the growing demand for peptides in various fields such as pharmaceuticals and biotechnology. Furthermore, regulatory constraints and safety concerns related to the use of peptides, especially in therapeutic applications, impose strict guidelines and approval processes, leading to delays and additional costs. These restraints collectively impede the expansion and advancement of the peptide synthesis market.

Peptide Synthesis Market Report Findings

https://www.globalinsightservices.com/reports/peptide-synthesis-market/

The equipment segment is anticipated to hold a majority of the Peptide Synthesis Market size throughout the study period.

Based on the product, the global market for peptide synthesis is divided into equipment, reagents & consumables, and others. Out of these equipment segment accounted for substantial market share in the year 2022.. The development of innovative peptide synthesis equipment has greatly contributed to the rapid growth of this segment in the global market. For instance, in February 2017, researchers at MIT introduced a new piece of equipment that enables faster peptide synthesis compared to existing options. This automated machine can create links between amino acids in just approximately 37 seconds, allowing for the production of large quantities of customized peptides in a shorter timeframe. On the other hand, reagents and consumables have generated the highest revenue among other peptide synthesis products. This is mainly due to their regular use in peptide synthesis protocols. Furthermore, recent advancements in peptide coupling reagents are expected to further drive market growth in the upcoming years.

The Liquid Phase Peptide Synthesis (LPPS) segment is anticipated to hold a majority of the Peptide Synthesis Market size throughout the study period.

By technology, the industry is bifurcated into Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), and Hybrid & Recombinant Technology. Liquid-phase peptide synthesis has dominated the global market throughout the projected period, while solid-phase peptide synthesis has exhibited the fastest growth from 2022 to 2032. The integration of automation and advancements in both liquid and solid-phase peptide synthesis has significantly contributed to cost reduction in peptide synthesis, driving its adoption worldwide and leading to increased global revenue. Traditional studies suggest that solid-phase peptide synthesis is a suitable approach for GMP manufacturing and API process development, particularly for cost-effective synthesis of long peptide sequences (more than 10 amino acids) in smaller volumes. However, purification costs during solid-phase peptide synthesis can increase manufacturing costs at any production scale. On the other hand, liquid-phase peptide synthesis is commonly used for developing shorter peptide sequences and larger volumes. Hybrid approaches are employed for synthesizing long sequences in large volumes.

The therapeutics segment is likely to hold a dominant Peptide Synthesis Market share and grow at a substantial CAGR during the forecast period.

Based on application, the industry is categorized into therapeutics, diagnosis, and research. The therapeutics segment, which includes various medical areas such as cancer, metabolic disorders, cardiovascular disorders, respiratory conditions, gastrointestinal disorders, infectious diseases, pain management, dermatology, central nervous system disorders, renal conditions, and others, was the leading revenue generator in the year 2022. This segment is anticipated to maintain its dominance throughout the forecast period.

On the other hand, the diagnosis segment is projected to experience the fastest growth from 2019 to 2026. The use of synthesized peptides in cancer treatment has significantly contributed to the revenue generated by the therapeutics segment, making it a major contributor in this market. Furthermore, within the therapeutics segment, the metabolic disorders segment is expected to exhibit the highest growth rate over the forecast period. This growth can be attributed to the presence of a robust pipeline and a substantial number of peptide candidates for treating type II diabetes. The discovery of novel peptides that play a crucial role in metabolic regulation is anticipated to provide valuable insights for the development of effective therapeutic approaches.

The Pharmaceutical & Biotechnology Companies segment is anticipated to hold a majority of the Peptide Synthesis Market size throughout the study period.

Based on end-user, the Peptide Synthesis market is divided into Pharmaceutical & Biotechnology Companies, Contract Development and Manufacturing Organization (CDMO), and Academic and Research Institutes. Among these, pharmaceutical and biotechnology companies are accounted for significant market share in 2022. This is owing to peptide therapies are gaining popularity in the pharmaceutical and biotechnology industries due to their cost-effectiveness, efficiency, and lower toxicity. The market for peptide synthesis is being driven by rapid advancements in peptide synthesizers and a robust pipeline of peptide therapeutics. In a 2022 article titled “Advances in oral peptide drug nanoparticles for diabetes mellitus treatment” published in Science Direct, it was highlighted that oral administration of peptide medications holds promise for treating diabetes mellitus. This approach is considered advantageous over traditional parenteral administration methods due to its simplicity and high patient compliance.

The growth of the market is further fueled by product launches, mergers, acquisitions, and the presence of competitors. An example of this is the world’s first “Peptide In A Pill” launched by Novo Nordisk India in January 2022. The peptide, Semaglutide, belongs to the GLP-1 receptor analog (GLP-1 RA) drug class and is used for managing type 2 diabetes. These developments are anticipated to drive the expansion of the pharmaceutical and biotechnology end-user segment in the peptide synthesis market.

The North America region is estimated to exhibit the highest growth rate during the Peptide Synthesis Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is projected to maintain its dominant position in the peptide synthesis market throughout the forecast period. This dominance can be attributed to the presence of advanced healthcare infrastructure and substantial investments by key players in North America. These investments aim to develop new peptide synthesis technologies, further fueling market expansion. For instance, in 2020, the United States Food and Drug Administration (US FDA) approved Imcivree (setmelanotide), a peptide derived from pro-opiomelanocortin, for chronic weight management in patients aged six years and older with obesity caused by rare genetic conditions. The US FDA’s accelerated drug approval initiative also plays a significant role in driving market growth in the region. These factors collectively contribute to North America’s outstanding market share in the global peptide synthesis market.

Moreover, increasing prevalence of obesity caused by sedentary lifestyles, poor dietary habits, and lack of physical activity, leading to various chronic diseases like diabetes in the United States. Effective treatment options are necessary to address these health concerns. For example, according to the International Diabetic Federation’s 2021 report, the North America Caribbean (NAC) region had an estimated 51 million adults aged 20-29 years living with diabetes, representing a regional prevalence of 14.6%. Additionally, this region has the second highest number of children and adolescents with type 1 diabetes, reaching 193,000 cases. The high prevalence of diabetes is expected to persist, resulting in a higher demand for peptide therapeutics and driving market growth in this region.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS20547/

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Peptide Synthesis market include Bachem Holding AG, Thermo Fisher Scientific, Merck KGaA, GenScript Biotech Corporation, Kaneka Corporation, Biotage AB, Syngene International Ltd. , Mesa Laboratories inc. , CEM Corporation and ProteoGenix, among others.

Recent Developments in the Peptide Synthesis Market:

• In June 2022, Evonik launched a new peptide to boost the productivity of cell-culture-based biopharmaceuticals. cQrex AC is a chemically defined and highly soluble source of L-cystine that enables a sufficient supply of this key amino acid to cells.
• In May 2022, the United States Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Mounjaro is a type of drug called a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

Peptide Synthesis Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current Peptide Synthesis Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
• The report also covers qualitative as well as quantitative analysis of the Peptide Synthesis market in terms of revenue ($Million)
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Peptide Synthesis Market industry.
• A thorough analysis of market trends and restraints is provided
• By region as well as country market analysis is also presented in this report
• Analytical depiction of the Peptide Synthesis Market along with the current trends and future estimations to depict imminent investment pockets. The overall Peptide Synthesis Market Industry opportunity is examined by understanding profitable trends to gain a stronger foothold
• Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Peptide Synthesis Market are also analyzed.

Global Peptide Synthesis Market Segmentation

By Product

• Equipment
• Reagents & Consumables
• Others

By Technology

• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid & Recombinant Technology

By Application

• Therapeutics
• Diagnosis
• Research

By End-user

• Pharmaceutical & Biotechnology Companies
• Contract Development & Manufacturing Organization/Contract Research Organization
• Academic & Research Institutes

By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Switzerland
  • Russia
  • Rest of Europe
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Singapore
  • Indonesia
  • Rest of Asia-Pacific
• Rest of the World
  • Latin America
  • Middle East
  • Africa

Key Players

• Bachem Holding AG
• Thermo Fisher Scientific
• Merck KGaA
• GenScript Biotech Corporation
• Kaneka Corporation
• Biotage AB
• Syngene International Ltd.
• Mesa Laboratories inc.
• CEM Corporation
• ProteoGenix

Hormone Replacement Therapy Market to Reach US$ 36.4 bn by 2032, driven by the rising incidence of target diseases and the availability of long-acting hGH products: Global Insight Services

New York, July  2023: According to a new research study by Global Insight Services (GIS), the global Hormone Replacement Therapy Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 36.4 bn by 2032.

hormone replacement therapy (HRT) is a treatment technique for replacing and/or replenishing hormones in the human body, which are at inadequate levels than those required for the normal physiology of the human body. The most prominent application of HRT is in the treatment of symptom alleviation of menopause.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS21882

Hormone Replacement Therapy Market: Key Trends and Drivers

One significant growth driver for the Hormone Replacement Therapy (HRT) market is the increasing awareness and acceptance of hormone replacement therapies for managing symptoms associated with menopause. As more women become educated about the benefits of HRT in alleviating hot flashes, night sweats, vaginal dryness, and other menopausal symptoms, the demand for these therapies is expected to rise. Moreover, with advancements in medical research and technology, the development of innovative and more targeted hormone therapies has become possible, catering to individual patient needs and preferences. This expanding range of treatment options, coupled with a growing aging population worldwide, is anticipated to fuel the growth of the HRT market in the coming years.

Hormone Replacement Therapy Market: Restraints & Challenges

One of the key restraints in the Hormone Replacement Therapy (HRT) market is the potential risk associated with long-term use of hormone replacement products. While HRT can provide relief from menopausal symptoms and other hormonal imbalances, studies have suggested an increased risk of certain health conditions, such as cardiovascular diseases and certain types of cancer, with prolonged use of HRT. These safety concerns have led to cautious prescribing practices and decreased patient acceptance, limiting the growth potential of the HRT market. Additionally, the availability of alternative therapies and the preference for non-hormonal treatment options further restraining the market growth.

Hormone Replacement Therapy Market Report Findings

https://www.globalinsightservices.com/reports/hormone-replacement-therapy-market/

The estrogen and progesterone replacement therapy segment is anticipated to hold a majority of the Hormone Replacement Therapy Market size throughout the study period.

Based on Therapy Type, it is analyzed across Estrogen Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy, and Progestogen Hormone Replacement Therapy. Among these, the estrogen and progesterone replacement therapy segment emerged as the dominant market leader in the Hormone Replacement Therapy industry. This significant market share can be attributed to the rising demand for hormone replacement therapies among individuals experiencing hormonal imbalances or undergoing menopause. According to the American Congress of Obstetricians and Gynecologists, around 6,000 women reach menopause daily in the U.S. Estrogen and progesterone replacement therapies are widely used to alleviate symptoms and promote overall well-being, thereby driving the growth of this particular segment in the Hormone Replacement Therapy market.

Moreover, advancements in Hormone Replacement Therapy technologies and the availability of innovative delivery systems have further propelled the adoption of estrogen and progesterone replacement therapy. As the aging population continues to expand globally and individuals seek ways to manage hormonal imbalances and associated symptoms, the estrogen and progesterone replacement therapy segment is expected to maintain its strong market position. The Hormone Replacement Therapy market will continue to witness significant growth, driven by the increasing demand for hormone replacement products and ongoing research to develop novel peptides that offer enhanced efficacy and improved patient outcomes.

The parenteral segment is likely to hold a dominant Hormone Replacement Therapy Market share and grow at a substantial CAGR during the forecast period.

Based on route of administration, it is categorized into parenteral, oral, and transdermal. During the projected period, the parenteral segment is anticipated to experience significant growth. This growth can be attributed to advancements in drug delivery methods, particularly through pen-based drug delivery systems. These systems are expected to enhance patient compliance and simplify administration, thus driving the expansion of this segment. Some popular pen-based products include the Genotropin Mixer Pen, Norditropin FlexPro Pen, and Humatrope HumatroPen.

Additionally, the introduction of a new long-acting growth hormone injection is predicted to further fuel the growth of this segment. For example, in January 2022, Pfizer, Inc. and OPKO Health, Inc. obtained approval from the Ministry of Health, Labour and Welfare in Japan to market NGENLA, a next-generation long-acting growth hormone injection for treating growth hormone disorders. This product offers the advantage of a once-a-week dosage regimen, contributing to its potential impact on segment growth.

The hypothyroidism Companies segment is anticipated to hold a majority of the Hormone Replacement Therapy Market size throughout the study period.

On the basis of Indication, it is segmented into Hypothyroidism, Menopause, Male Hypogonadism, Growth Hormone Deficiency, and Others. In 2022, the the hypoparathyroidism segment is anticipated to experience substantial growth in the forecast period, driven by the development of novel treatments and the introduction of new products. For instance, in September 2020, Ascendis Pharma A/S presented its TransCon technologies at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting. The company also disclosed the top-line results of the phase 2 clinical trial for TransCon PTH at the same event. Currently, the drug is undergoing phase 3 clinical trials. Upon approval and subsequent launch, this product will offer additional options for parathyroid hormone replacement therapy

On the other hand, menopause segment emerged as the dominant force in the market, capturing a share. This can be attributed to the rising number of women experiencing menopause. According to the UN’s 2020 global estimates, there were 958 million women aged 50 and above, and this number is projected to reach 1.65 billion by 2050. As a result, a significant population of women is expected to spend a considerable portion of their lives after menopause in the future. However, the age of menopause can vary due to various factors, including natural factors such as habitat and genetics, which influence the timing of menopause for individuals.

The North America region is estimated to exhibit the highest growth rate during the Hormone Replacement Therapy Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is projected to maintain its dominant position in the Hormone Replacement Therapy market throughout the forecast period. This region is expected to experience substantial growth throughout the forecast period. The significant market share can be attributed to several factors, including major product launches, collaborative agreements among manufacturers, and favorable reimbursement policies. An example of such a success is the approval of Sogroya (somapacitan-beco), a hormone replacement therapy product developed by Novo Nordisk A/S, by the U.S. FDA in August 2020. This particular product is administered once weekly via the subcutaneous route and is targeted towards adults diagnosed with growth hormone deficiency. The region’s strong healthcare infrastructure, increasing geriatric population, rising prevalence of hormonal disorders, and extensive research and development activities contribute to its leadership position. Additionally, favorable reimbursement policies, high healthcare expenditure, and robust pharmaceutical industry further propel the growth of the HRT market in North America, attracting both domestic and international players to invest in this lucrative market segment..

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS21882/

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Hormone Replacement Therapy market include AbbVie (U.S.), Allergan plc (U.S.), Amgen (U.S.), Bayer AG (Germany), Belmar Pharma Solutions (U.S.), Endo International plc (Ireland), Merck KGaA (Germany), Mithra Pharmaceuticals (Belgium), Novo Nordisk A/S (Denmark), and Pfizer Inc. (U.S.)., among others.

Recent Developments in the Hormone Replacement Therapy Market:

• In February 2023, Korea’s Ministry of Food and Drug Safety approved Pfizer’s NGENLA for the treatment of growth hormone deficiency.
• In June 2022, Halozyme Therapeutics, Inc. announced the commercial launch of TLANDO (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
• In February 2022, Pfizer Inc. and OPKO Health, Inc. announced that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA, a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.
• In January 2022, Pfizer, Inc. and OPKO Health, Inc. received approval from the Ministry of Health, Labour and Welfare, Japan, for the commercialization of NGENLA to treat growth hormone disorder. This product is the next-generation long-acting growth hormone injection, with a treatment frequency of a once-a-week dosage.
• In November 2021, I-MAB Biopharma Co., Ltd. entered into a collaboration with Jumpcan Pharmaceutical Group for the development & commercialization of eftansomatropin alfa (TJ101) in China. TJ101 is a long-acting recombinant human growth hormone, which is currently under phase 3 clinical trial for the treatment of pediatric growth hormone deficiency. This collaboration is expected to strengthen its position in the hormone replacement therapy market.
• In September 2020, Ascendis Pharma A/S showcased the TransCon technologies at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting. It also published the top-line results of the phase 2 clinical trial for TransCon PTH at the annual meeting. The drug is currently in phase 3 clinical trials. The approval and subsequent launch of this product will provide more options available for parathyroid hormone replacemen
• In August 2020, U.S. FDA approved Sogroya (somapacitan-beco) a HGH replacement therapy product developed by Novo Nordisk A/S. This product is administered once a weekly through subcutaneous route in adults diagnosed with growth hormone deficiency.

Hormone Replacement Therapy Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current Hormone Replacement Therapy Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
• The report also covers qualitative as well as quantitative analysis of the Hormone Replacement Therapy market in terms of revenue ($Million)
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Hormone Replacement Therapy Market industry.
• A thorough analysis of market trends and restraints is provided
• By region as well as country market analysis is also presented in this report
• Analytical depiction of the Hormone Replacement Therapy Market along with the current trends and future estimations to depict imminent investment pockets. The overall Hormone Replacement Therapy Market Industry opportunity is examined by understanding profitable trends to gain a stronger foothold
• Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Hormone Replacement Therapy Market are also analyzed.

Global Hormone Replacement Therapy Market Segmentation

By Therapy Type

• Estrogen Hormone Replacement Therapy
• Human Growth Hormone Replacement Therapy
• Thyroid Hormone Replacement Therapy
• Testosterone Hormone Replacement Therapy
• Progestogen Hormone Replacement Therapy

By Route of Administration

• Oral
• Parenteral
• Transdermal

By Indication

• Menopause
• Hypothyroidism
• Male Hypogonadism
• Growth Hormone Deficiency
• Others

By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Switzerland
  • Russia
  • Rest of Europe
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Singapore
  • Indonesia
  • Rest of Asia-Pacific
• Rest of the World
  • Latin America
  • Middle East
  • Africa

Key Players

• AbbVie (U.S.)
• Allergan plc (U.S.)
• Amgen (U.S.)
• Bayer AG (Germany)
• Belmar Pharma Solutions (U.S.)
• Endo International plc (Ireland)
• Merck KGaA (Germany)
• Mithra Pharmaceuticals (Belgium)
• Novo Nordisk A/S (Denmark)
• Pfizer Inc. (U.S.)

Vaccine Market to Reach US$ 128.6 Bn by 2032, driven by   newly emerging infectious pathogenic diseases has influenced the need for effective vaccines across the globe: Global Insight Services

New York, June 2023: According to a new research study by Global Insight Services (GIS), the global Vaccine Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $128.6 Billion by 2032.

A vaccine is a biological which is used to boost the person’s immune system and help to provide immunization against chronic diseases. The suspension consists of either weakened or killed forms of disease-causing microorganisms that enhance immunity without causing diseases. The vaccine provides active immunity against a specific harmful agent such as diseases caused by a certain pathogen, injection, bacteria, virus, or parasites. By stimulating the immune system to attack the agent and eliminating these agents and increasing the life of adults and elderly individuals. After stimulation by a vaccine, B lymphocytes remain sensitized and ready to respond to the agent whenever it enters the body next time.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10524

Vaccine Market: Key Trends and Drivers

The expanding availability of preventive as well as therapeutic vaccines for range of diseases will boost the market expansion. Furthermore, newly emerging infectious pathogenic diseases has influenced the need for effective vaccines across the globe. This has driven the R&D activities undertaken by the operational players as well as dedicated research institutes. Advancement in vaccine development technologies to increase its efficacy and liability will offer innovative solutions to address existing disease burden. The adoption of novel development approaches including DNA/RNA vaccines, nanoparticle vaccines, and rational design will foster the vaccines market expansion.

Vaccine Market: Restraints & Challenges

Some of the market obstacles include a scarcity of experienced specialists and significant investment costs, as well as legal and ethical concerns about the market methods and outcomes in numerous nations.

Vaccine Market Report Findings

https://www.globalinsightservices.com/reports/vaccine-market/

The adult segment is likely to hold a dominant Vaccine Market share and grow at a substantial CAGR during the forecast period.

Based on age group, the market is bifurcated into Pediatric, and Adult. Adult vaccines segment is projected to proceed at xx% CAGR during the forecast timeframe. This is attributable to the increasing awareness about the importance of immunization and advancements in vaccine technology, more adults are actively seeking vaccination against various diseases. The rise in chronic conditions, such as heart disease, diabetes, and respiratory illnesses, has further propelled the demand for adult vaccines. Additionally, the COVID-19 pandemic has highlighted the critical need for adult vaccinations, leading to a surge in vaccine uptake. As a result, pharmaceutical companies and healthcare providers are focusing on expanding their adult vaccine portfolios and improving accessibility to cater to this growing market segment. Additionally, some countries have established the vaccination policies and regulations for adults while travelling to particular nations to avoid the risk of disease transmission, that has further influenced the vaccination rate in adults.

The Inactivated segment is anticipated to hold a majority of the Vaccine Market size throughout the study period.

Based on the technology, the market is bifurcated into Conjugate, Live, Inactivated, Recombinant, Toxoid. Vaccines market from inactivated segment exceeded USD xx billion in 2022. This is attributed to the ability of inactivated vaccines in destruction of pathogen replication. This offers effective protection against various dreadful pathogenic diseases such as hepatitis A, influenza, polio, and rabies. Moreover, these vaccines prevent the reversal activity of pathogens to more pathogenic phenotype and avoids the interference with other functional molecules during the combination therapies. This leads to preference for inactivated technology over the live vaccines. Furthermore, as it can stored without refrigeration for certain period as the pathogen is dead, it offers ease in transportation and storage that will continue to increase its demand.

The COVID-19 segment is anticipated to hold a majority of the Vaccine Market size throughout the study period.

Based on the application, the market is bifurcated into Cancer, Hepatitis, Pneumococcal Disease, Influenza, Rotavirus, COVID-19, and others. Among these the Covid-19 vaccine segment has experienced remarkable growth within the vaccine market. Since the emergence of the pandemic, the urgent need for effective vaccines has driven extensive research, development, and manufacturing efforts worldwide. The unprecedented global demand for Covid-19 vaccines has led to a surge in production and distribution capabilities, with numerous pharmaceutical companies, governments, and international organizations actively participating in the vaccination campaigns. This growth has been fueled by the imperative to curb the spread of the virus, alleviate the strain on healthcare systems, and restore economic stability. The Covid-19 vaccine segment’s rapid expansion has not only contributed significantly to saving lives and reducing the severity of the disease but has also propelled advancements in vaccine technology and infrastructure, fostering innovation and resilience in the broader vaccine market.

The Europe region is estimated to exhibit the highest growth rate during the Vaccine Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World.  Europe vaccines market accounted for xx% revenue share in 2022. This is attributable to the adoption of new technologies and expanding awareness about the preventive vaccines in the region. The government organizations are implementing some strategies to broaden accessibility for the emerging infectious disease treatments including the COVID-19. In addition, the industry players entered in collaboration with non-government organizations to provide COVID-19 vaccines considering significantly increasing disease incidence in the region.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10524/

Competitive Landscape

The global Vaccine Market report includes players are AstraZeneca plc., CSL Limited, Emergent BioSolutions Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Novavax, Pfizer Inc, Sanofi S.A., and Serum Institute of India, among others.

Recent Developments in the Blood-Brain Barrier Market:

• In February 2021, Ceva partnered with the French National Research Institute for Agriculture, Food, and Environment (INRAE) for R&D in the prevention of infectious diseases from animal origin and improvement of animal health.
• In January 2021, Zoetis launched the Poulvac Procerta HVT-IBD vaccine for the protection of poultry against Infectious Bursal Disease (IBD). This added to the company line of recombinant vector vaccines.
• UNICEF and Pfizer entered into a supply agreement for the COVID-19 vaccines distribution throughout 2021. This has helped the company to maintain broaden its distribution across the globe, thereby driving the business revenue.

Vaccine Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Vaccine Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Vaccine Market potential from 2022 to 2032 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Vaccine Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Vaccine Market Segmentation

By Age Group

• Pediatric
• Adult

By Technology

• Conjugated
• Live
• Inactivated
• Recombinant
• Toxoid
• Others

By Application

• Cancer
• Hepatitis
• Pneumococcal Disease
• Influenza
• COVID-19
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• AstraZeneca plc.
• CSL Limited
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc.
• Johnson & Johnson
• Merck & Co.
• Novavax
• Pfizer Inc
• Sanofi S.A.
• Serum Institute of India

Pharmacovigilance Market to Reach US$ 18.4 bn by 2032, driven by The faster credit approval processes and ease of accessing the online platforms: Global Insight Services

New York, May 2023: According to a new research study by Global Insight Services (GIS), the global Pharmacovigilance Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 18.4 bn by 2032.

Pharmacovigilance is the science and activities related to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems. Passive surveillance is the most common type of pharmacovigilance activity. It is important because it can identify previously unknown adverse events. However, it has some limitations, such as under-reporting and reporting bias. Active surveillance is less common, but it is useful for monitoring drugs that are used to treat rare conditions. Experimental studies are the most reliable way to assess the safety of a new medicine, but they are usually only conducted during the development and approval process. Pharmacovigilance is a complex and ever-changing field. It requires close collaboration between healthcare professionals, patients and the pharmaceutical industry.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS22087/

Pharmacovigilance Market: Key Trends and Drivers

The key drivers of pharmacovigilance (PV) market are the increasing number of clinical trials, the growing prevalence of chronic and life-threatening diseases, and the need for better patient safety.

The number of clinical trials has been increasing over the years as the pharmaceutical industry seeks to develop new and better treatments for various diseases. This has led to an increase in the number of patients being exposed to new drugs, which has in turn led to an increase in the need for PV.

The prevalence of chronic and life-threatening diseases is also a key driver of the PV market. As the population ages, the number of people suffering from chronic diseases such as cancer and heart disease is increasing. This is leading to a greater need for PV, as these patients are often taking multiple medications that need to be closely monitored for safety.

Finally, the need for better patient safety is also driving the PV market. In recent years, there have been a number of high-profile cases of patients being harmed by drugs that were not properly monitored. This has led to calls for better PV, which is helping to drive the market.

Pharmacovigilance Market: Restraints & Challenges

The key restraints and challenges in Pharmacovigilance (PV) market include the following:

• Lack of awareness of PV among patients and healthcare professionals: There is a lack of awareness of PV among patients and healthcare professionals. This is a challenge because it can lead to underreporting of adverse events and lack of data for safety monitoring.
• Lack of standardization: There is lack of standardization in PV, which is a challenge because it can lead to inconsistency in data collection and analysis.
• Limited resources: PV requires significant resources, which can be a challenge for many organizations.
• Lack of trained personnel: There is a lack of trained personnel in PV, which is a challenge because it can lead to errors in data collection and analysis.

Pharmacovigilance Market Report Findings

https://www.globalinsightservices.com/reports/pharmacovigilance-pv-market/

The phase IV segment is anticipated to hold a majority of the Pharmacovigilance Market size throughout the study period.

Based on the clinical trail phases, the Pharmacovigilance market is divided into Preclinical I, phase I, phase II, phase III, phase IV. The phase IV (post-marketing) segment led the overall market with over 75.8% share in 2022. These solutions act as an additional safety measure for the drugs undergoing clinical trials. Phase IV is an imperative stage of clinical trials as unsuspected adverse drug reactions can be detected in this stage. Therefore, the data collected and assessed during this stage is expected to be of the highest relevance owing to intensive drug testing on a large patient base of highest relevance after commercialization of the drug.

The phase III segment is expected to witness lucrative growth of 10.5% in the forecast period. Phase III trials are done to determine and establish the efficacy of drugs. These trials also provide additional information regarding possible drug interactions, drug safety, and effectiveness before the commercialization of the drug. The aforementioned factors are expected to boost revenue generation in the segment over the forecast period

The Contract outsourcing segment is anticipated to hold a majority of the Pharmacovigilance Market size throughout the study period.

By service provider, the industry is bifurcated into In-house, and Contract Outsourcing. Contract outsourcing held the dominant revenue share of over xx% in 2022 and is expected to witness the fastest CAGR of 10.6% for the forecast period. This can be attributed to the benefits associated with outsourcing such as risk mitigation, resource flexibility, reduction of upfront investments, and lower fixed costs. Contract outsourcing organizations provide solutions such as process design Standard Operating Procedure (SOP), PV audits, and other customized services.

The dynamic growth of the contract outsourcing segment can also be attributed to the rapidly emerging CROs providing end-to-end clinical trial solutions, especially in the emerging economies of Asia Pacific, such as India, China, and Japan, thereby enabling resources sharing, cost efficiency, resource flexibility, and expansion of operative capabilities. Outsourcing PV services is accompanied by benefits such as delivering services pertinent to highly complex regulatory requirements, helping to add scalability to accommodate growing product portfolios, and achieving aggressive cost targets. Contract outsourcing also helps reduce the complexity of clinical trials, allows faster approval of trials, and helps effective utilization of internal resources.

The Spontaneous reporting segment is likely to hold a dominant Pharmacovigilance Market share and grow at a substantial CAGR during the forecast period.

Based on Type of Reporting, the industry is categorized into Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, and EHR Mining. Spontaneous reporting held the largest share of over xx% in 2022 owing to wide usage in the detection of new, serious, and rare ADRs. Moreover, this segment serves as an efficient and inexpensive method. Wide usage of surveillance reports generated through this method by pharmaceutical industries and regulatory authorities is also responsible for the significant growth of the segment.

Cohort Event Monitoring (CEM) emerged as the second-largest segment in 2021 owing to its increasing application in the detection of a wide range of adverse clinical events. Conjugation of CEM with statistical tools and data mining systems such as longitudinal health records are responsible for the growing popularity of this type. It serves as an active form of surveillance method, which can also be used for new as well as older medicines, thus driving the segment.

The pharmaceuticals lending segment is anticipated to hold a majority of the Pharmacovigilance Market size throughout the study period.

Based on end-user, the Pharmacovigilance market is divided into Pharmaceuticals, Biotechnology Companies, Medical Device Manufacturers, and Others. In 2022, pharmaceuticals held the largest revenue share of over xx%. Outsourcing the pharmacovigilance process is practiced by pharma companies to avoid high upfront investments and fixed overhead costs, increase resource flexibility, and secure additional capacity. Outsourcing pharmacovigilance proves to be a cost-effective endeavor for small and medium-sized companies.

The biotechnology segment is anticipated to witness lucrative growth in the forthcoming years owing to increasing new product development activities in this sector. In recent years, drugs are being developed and consumed at increasingly high rates. The use of drugs over longer periods by a large population can lead to adverse effects not seen in clinical trials. For instance, Vioxx (an osteoarthritic/ acute pain medication) and Avandia (an anti-diabetic) were marketed for some time before a pattern of safety problems was detected with their use. The growing need for medical information among the regulatory authorities is also anticipated to drive the segment.

The North America region is estimated to exhibit the highest growth rate during the Pharmacovigilance Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America holds a major market share for pharmacovigilance and is expected to continue its stronghold for a few more years. Since pharmacovigilance activities are being shifted to contract research organizations (CROs) due to high costs, the pharmacovigilance approach in the United States is moving from a passive to a proactive role in the healthcare system. As per the Institute of Medicine report, by Christopher Cheney, published in March 2020, nearly 98,000 Americans died annually due to medication errors. Estimates of annual patient deaths due to medication errors have since risen steadily to 440,000 lives, which makes medication errors the country’s third-leading cause of death. Therefore, there is a need to modify the current protocols for quick communication between healthcare providers and the Food and Drug Administration. Since pharmacovigilance plays a vital role in drug assessment and prevention of adverse effects, the demand for such services is likely to increase in the near future.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS22087

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Pharmacovigilance market include Accenture, Cognizant, Laboratory Corporation of America Holdings, IBM Corporation, ArisGlobal, ICON plc., Capgemini, ITClinical, FMD K&L, IQVIA among others.

Recent Developments in the Pharmacovigilance Market:

• In June 2022, StellarFi, the U.S.-based public benefit corporation, launched its fintech platform, which is expected to help its users build their credit scores by paying their liabilities timely.
• In June 2022, a Singapore-based startup named Helicap raised USD 6.94 million in funding, and it has developed a technology for crunching data points of loans which can help in evaluating the creditworthiness of over 500 lenders across South East Asia and Oceania.
• In June 2022, Blueprint Capital Advisors, an alternative credit investment firm, struck a deal with T30 Capital LLC to scale the real estate lending platform.
• In May 2022, GoFundMe announced the acquisition of non-profit funding site Classy. Classy has been reported to continue and operate as a wholly-owned subsidiary of GoFundMe. The investment aims to create new opportunities to serve the nearly $ 500 billion philanthropic market as GoFundMe strives to be the most helpful place on the planet.
• In June 2021, MarketFinance Limited, the U.K.-based business finance lender, will embed the suite of its lending products inside the Funding Options application. This partnership is aimed to create seamless and quick accessibility to finance operations.

Pharmacovigilance Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Pharmacovigilance Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Pharmacovigilance Market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Pharmacovigilance Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Pharmacovigilance Market Segmentation

By Clinical Trial Phase

• Preclinical
• Phase I
• Phase II
• Phase III
• Phase IV

By Service Provider

• In-house
• Contract Outsourcing

By Type of Reporting

• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

By End User

• Pharmaceuticals
• Biotechnology Companies
• Medical Device Manufacturers
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• Accenture
• Cognizant
• Laboratory Corporation of America Holdings
• IBM Corporation
• ArisGlobal
• ICON plc.
• Capgemini
• ITClinical
• FMD K&L
• IQVIA

Ophthalmic Drugs Market to Reach US$ 68.574.4 mn by 2032, driven by include increasing incidences and prevalence of eye-related disorders, rising research and development about the development of novel drugs, and increasing focus on developing combination therapies: Global Insight Services

New York, May 2023: According to a new research study by Global Insight Services (GIS), the global Ophthalmic Drugs Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 68.574.4 mn by 2032.

The ophthalmic drugs are the formulations that are designed for the treatment of eye diseases such as cataract, glaucoma, color blindness, diabetic macular edema, cytomegalovirus (CMV) retinitis, and age-related macular degeneration (AMD).

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS21358

Ophthalmic Drugs Market: Key Trends and Drivers

Rise in Prevalence of Eye Disorders

In industrialized nations, the aging population increases life expectancy, and unfavorable changes in lifestyle, such as bad eating habits and reduced exercise, are anticipated to lead to a rise in the prevalence of illnesses that might impair eyesight in the future. The most frequent causes of visual impairment include hereditary retinal illnesses affecting young people, glaucoma, cataracts, and age-related macular degeneration, primarily among older folks. For instance, in October 2022, as per World Health Organization (WHO) facts on ‘Blindness and Vision Impairment,’ The yearly cost of productivity losses related to eye impairment is projected to be USD 411 billion, placing a tremendous financial burden on the whole world. However, vision loss may afflict people of all ages. The majority of persons with visual impairment and blindness are over the age of 50. A near- or distance vision impairment affects at least 2.2 billion individuals worldwide. Hence aforementioned factors will boost the market growth.

Ophthalmic Drugs Market: Restraints & Challenges

Challenges Associated with Formulation of Ophthalmic Drugs

One of the most difficult areas of the pharmaceutical industry, drug delivery to the human eye, is quickly expanding. It is challenging for medications to work at the site of action and endure over time due to the unique structure and physiology of the eye. Creating a therapeutic system that can deliver an ideal concentration of medication to the target region with high therapeutic efficacy is a challenge in ocular drug delivery systems. Due to the cornea’s architecture, physiology, and barrier properties, medicines are absorbed quickly; therefore, eye drop-inducing is necessary to maintain the therapeutic level in tear film or at specific spots. Consequences of utilizing medication solutions often include the potential for toxicity at the ocular surface and cellular damage.

Due to precorneal loss, including solution drainage, lacrimation, tear dynamics, tear dilution, conjunctival absorption, non-productive absorption, the temporary resident period in the cul-de-sac, and tear turnover, the majority of ocular dose forms have low bioavailability. Other difficulties include the impermeable corneal epithelial barrier, making it difficult to transport medications to the anterior area after topical administration.

Ophthalmic Drugs Market Report Findings

https://www.globalinsightservices.com/reports/ophthalmic-drugs-market/

The prescription segment is anticipated to hold a majority of the Ophthalmic Drugs Market size throughout the study period.

On the basis of product type, the global ophthalmic drugs market is segmented into prescription drugs, over the counter drugs. Among these, the prescription drugs segment is going to dominate the market over the forecast period. A prescription drug also known as prescription medication, prescription medicine or prescription-only medication) is a pharmaceutical drug that is only permitted to be dispensed to those with a medical prescription. The increased prevalence of illnesses such as AMD and diabetic retinopathy accounts for the expansion of the prescription medications category. Furthermore, improved efficacy and safety are two factors that are likely to drive prescription segment demand. Lotemax gel/ointment, Zylet, Durezol, bepreve (bepotastine besylate ophthalmic solution), and prescription synthetic tears are among the medications available in this market. Bepreve is an antihistamine used for the treatment of allergic conjunctivitis. Some prescription medications contain moisturizing and lubricating agents that temporarily increase tear secretion. Prescription drugs are thought to be more effective than over-the-counter treatments in treating ocular problems.

The dry eye segment is anticipated to hold a majority of the Ophthalmic Drugs Market size throughout the study period.

Based on disease, the industry is categorized into Eye Allergy, Eye Infection, Glaucoma, Retinal disorders, Dry Eye, Other. The dry eye segment is anticipated to witness the fastest growth during the forecast period. The segment was valued at USD 5,371.7 million in 2022 and it is expected to grow further to USD 11,919.8 million by 2032, at a rate of 7.9% during the forecast period. The factor such as the growing demand for effective treatments, the rising prevalence of dry eye disease, the presence of a lucrative pipeline, and increasing awareness among the population about the condition. The COVID-19 outbreak had an adverse impact on the market in the early phase of the pandemic attributable to the reduced ophthalmology visits. However, as soon as the eye care practices began the market demonstrated a rebound. Moreover, the dry eye persisted in SARS-CoV-2 patients even after treatment of the disease, thus, increasing the target population for treatments. Moreover, during the pandemic sedentary activities and more use of screen has increased the occurrence of dry eye symptoms. Increasing R&D activities for treating the condition have developed a strong and promising pipeline.

The topical segment is likely to hold a dominant Ophthalmic Drugs Market share and grow at a substantial CAGR during the forecast period.

Based on route of administration, the industry is categorized into oral, topical, and systemic. The topical segment was valued at USD 20,712.8 million in 2022 and it is anticipated to grow further to USD 39,786.5 million by 2032, at a CAGR of 6.4% during the forecast period. The factors which are the driving the topical segment are the rising demand for topical medicines due to easy doses, patient compliance issues, and different strategic initiatives performed by market participants account for the expansion of the topical sector. Suspensions, remedies, and ointments are common topical medication dose forms. The cornea is the principal route of topical absorption that faces substantial anatomical challenges. The availability of various medications administered topically is thought to be the primary driver of this market. For example, Allergan, an AbbVie Inc. subsidiary, reported in October 2021 that the US FDA has authorized VUITY for the treatment of presbyopia. Vuity is the only FDA-approved eye drop for the treatment of a variety of eye disorders. The topical route segment is expected to yield the most income throughout the anticipated term. Existing formulas are being replaced as more novel products are introduced to the market, which will drive market growth in the coming years.

The eye drop lending segment is anticipated to hold a majority of the Ophthalmic Drugs Market size throughout the study period.

Based on dosage form, the Ophthalmic Drugs market is divided into Gels, Eye Solutions & Suspensions, Capsules and Tablets, Eye Drops, and Ointments. The capsules and tablets segment was valued at USD 9,341.1 Million in 2022. Factor such as increasing health consciousness among the individuals coupled with advancements in manufacturing technology and the introduction of new materials. This will added more features to the traditional capsules such as controlled drug release, tamper-evident, and formulation choice of potent APIS due to reduced degradation in stomach pH, appealing aesthetics, and longer shelf life. In recent times, manufacturers are focusing on developing non-gelatin-based capsules using plant-based polymers. Starch, HPMC, and gums such as Pullulan. Increasing launch of tablet and capsule will fuel the segmental growth. For instance, In April 2022, Wellbeing Nutrition released “Melts Eye Care,” the world’s first all-natural eye vitamin.

The Anti-VEGF segment is anticipated to hold a majority of the Ophthalmic Drugs Market size throughout the study period.

Based on drug class, the Ophthalmic Drugs market is divided into Antiallergy, Anti-inflammatory, Anti-VEGF Agents, Anti-glaucoma, and Others. The Capsules and Tablets segment was valued at USD 9,341.1 Million in 2022. Factor such as increasing health consciousness among the individuals coupled with advancements in manufacturing technology and the introduction of new materials. This will added more features to the traditional capsules such as controlled drug release, tamper-evident, and formulation choice of potent APIS due to reduced degradation in stomach pH, appealing aesthetics, and longer shelf life. In recent times, manufacturers are focusing on developing non-gelatin-based capsules using plant-based polymers. Starch, HPMC, and gums such as Pullulan. Increasing launch of tablet and capsule will fuel the segmental growth. For instance, In April 2022, Wellbeing Nutrition released “Melts Eye Care,” the world’s first all-natural eye vitamin.

The North America region is estimated to exhibit the highest growth rate during the Ophthalmic Drugs Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the Ophthalmic Drugs Market growth, recording the highest CAGR during the forecast period. Among all other regions, North America holds the largest market share over the forecast period. There are numerous market players in the North American region, and as more individuals learn about the items’ accessibility, ophthalmic pharmaceutical sales will increase. Both the healthcare infrastructure and consumer knowledge are of the highest calibre in this region. These two elements will be essential to the market’s growth over the course of the projection period.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS21358/

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global ophthalmic drugs market includes players such as Pfizer Inc., Sterling Pharmaceutical Services LLC, Somerset Pharma, LLC, Alcon Inc., Novartis AG, Bayer AG, Nicox SA, Coherus BioSciences, Inc., Sun Pharmaceutical Industries, Inc., Krishlar Pharmaceuticals, Allergan (AbbVie Inc), and others.

Recent Developments in the Ophthalmic Drugs Market:

• In May 2023, Alcon launched TOTAL30® for Astigmatism, the first and only reusable contact lens with Water Gradient material for astigmatic contact lens wearers.
• In September 2022, Alcon has announced new products introductions in the United States at AA). Clareon Toric IOL is introduced by Alcon, which is completing the Clareon Collection. Fidelis and patient involvement are expanding Alcon’s digital capabilities. Given international surgical backlogs and personnel limitations, the demand for remote, digital solutions in ophthalmology has never been stronger.
• In April 2022, Sandoz announced the release of its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, an AB-rated generic counterpart to AbbVie’s COMBIGAN, to treat ocular hypertension (high eye pressure) in patients.
• In March 2022, Nicox SA announced encouraging findings from a Chinese Phase 3 clinical trial of ZERVIATE (cetirizine ophthalmic solution), 0.24%, conducted by Ocumension Therapeutics, its Chinese partner. The antihistamine ZERVIATE has compared to emedastine difumarate ophthalmic solution, 0.05%, which is sold under the trade name EMADINE.

Ophthalmic Drugs Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Ophthalmic Drugs Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Ophthalmic Drugs Market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Ophthalmic Drugs Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Ophthalmic Drugs Market Segmentation

By Product Type

• Prescription Drugs
• OTC Drugs

By Disease

• Dry Eye
• Eye Allergy
• Glaucoma
• Eye Infection
• Retinal Disorders
• Uveitis & Others

By Route of Administration

• Topical
• Local Ocular
• Systemic

By Dosage Form

• Gels
• Eye Solutions & Suspensions
• Capsules and Tablets
• Eye Drops
• Ointments

By Drug Class

• Antiallergy
• Anti-inflammatory
• Anti-VEGF Agents
• Anti-glaucoma
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Pfizer Inc
• Sun Pharmaceutical Industries, Inc.
• Bayer AG
• Alcon Inc.
• Allergan (AbbVie Inc)
• Coherus BioSciences, Inc.
• Krishlar Pharmaceuticals
• Nicox SA
• Sterling Pharmaceutical Services LLC
• Somerset Pharma, LLC

Proteomics Market to Reach US$ 68.4 Bn by 2032, driven by Increasing investment in research and development activities: Global Insight Services

New York, April 2023: According to a new research study by Global Insight Services (GIS), the global Proteomics Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 68.4 Billion by 2032.

Proteomics is the large-scale study of proteins, including their structure, function, and interactions. Proteins are the main components of cells and play a vital role in all biological processes. By understanding proteins, we can better understand how cells work and how diseases develop. Proteomics research often uses high-throughput techniques to analyze thousands of proteins at once. This allows us to identify patterns and trends that would be difficult to see using traditional methods. Proteomics has been used to discover new proteins, understand the function of existing proteins, and develop new drugs and diagnostic tests.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS20619/

Proteomics Market: Key Trends and Drivers

The rising prevalence of chronic diseases like cancer, Cardiovascular Diseases (CVDs), respiratory diseases, CKD, and others is another factor anticipated to propel the market growth. For instance, according to Globocan, in December 2020, there were 19.3 million new cases of cancer across the world and 10 million cancer-related deaths were reported. Similarly, CVDs are one of the major causes of death worldwide. For instance, as per the WHO (2021), target diseases kill 41 million patients per year. Thus, owing to the increasing prevalence of life-threatening diseases, the demand for personalized therapies is also increasing resulting in a positive impact on the industry.

Proteomics Market: Restraints & Challenges

Proteomics is the large-scale study of proteins, their structures and functions. It is a relatively new field, only coming into its own in the late 1990s with the advent of new technologies that allow for the rapid identification and characterization of proteins.

Despite its promise, proteomics faces a number of key challenges that must be overcome if it is to fulfill its potential. Perhaps the most significant challenge is the sheer size and complexity of the proteome. The human proteome is estimated to contain upwards of 20,000 different proteins, each with its own unique structure and function. Understanding the role of all of these proteins in health and disease is a daunting task.

Another challenge facing proteomics is the lack of standardization. Unlike genomics, which has benefited from years of research and standardization efforts, proteomics is still in its early stages. This lack of standardization makes it difficult to compare results across different studies and to replicate findings. Finally, proteomics is an expensive field of research. The cost of the necessary equipment and reagents can be prohibitive, making it difficult for many laboratories to get started in proteomics.

Proteomics Market Report Findings

https://www.globalinsightservices.com/reports/proteomics-market/

The Electrophoresis equipment segment is likely to hold a dominant Proteomics Market share and grow at a substantial CAGR during the forecast period.

By product, the market is segmented into Spectroscopy, Chromatography, Electrophoresis, Protein Microarrays, and Others. Electrophoresis equipment and biochip analyzers are the commonly used instruments for protein analysis. Furthermore, the increasing demand for automation in diagnostic techniques and the need for a cost-effective platform for sample analysishave increased interest among manufacturers to focus on innovations and product development. Moreover, technological breakthroughs (the growing downsizing and integration of biochips as well as advancements in the instruments and workflows for mass spectrometry) in proteomics instruments are expected to drive market trends over the years to come.

The drug discovery segment is anticipated to hold a majority of the Proteomics Market size throughout the study period.

By application, the proteomics market is classified into clinical diagnostics, drug discovery, and other application. The drug discovery segment dominated the global market with a revenue share of over xx% in 2022. On the other hand, the drug discovery segment is estimated to register the fastest growth rate during the projected period. The development of structure-based drug design, a greater emphasis on creating personalized drugs, and more investments in these areas can all be credited for the segment growth. In addition, proteomics technologies also offer a way to show early on in a drug discovery program, saving pharmaceutical corporations a significant amount of capital and eventually benefiting patients as well as the healthcare systems, which contributes to the segment growth.

The clinical laboratories segment is anticipated to hold a majority of the Proteomics Market size throughout the study period.

Based on end-user. It is segmented into hospitals, clinical laboratories, pharmaceutical companies, academic research laboratories, and others. Clinical laboratories was the market’s dominant segment in 2022. This is due to the widespread use of protein analysis by researchers and clinicians to identify illness biomarkers for early detection and detecting individual risk factors. This is expected to provide new avenues for disease early detection and prevention. It is feasible to discover prospective biomarkers and protein transcriptional regulation that can be used to identify and predict malignancies, as well as evaluate their prognosis, using proteomics-based diagnosis, which promotes the segment’s growth.

The North America region is estimated to exhibit the highest growth rate during the Proteomics Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The North American market is primarily driven by the rise in demand for the preservation of blood, solid tissue specimens, including paraffin-embedded or frozen bio-specimen of tumors, and other tissues (like peripheral blood cells, bone marrow, and stem cells-derived cord blood and its derivatives), across multiple research institutes, pathological centers, and hospitals. The surge in the government’s investment in drug discovery is projected to boost the biopreservation utility for the preservation of cells, tissues, and organs ex-vivo for the purpose of storage, shipment, and transportation. For instance, the Canadian government invested USD 45 million in the current year over the next three years to the Stem Cell Network to encourage stem cell and regenerative medicine research. Such investments are anticipated to boost the utility and demand of biopreservation in the region, thereby boosting market growth during the forecast period.

Additionally, advancements in technology, increasing product approvals, partnerships, and acquisitions by key players are helping in the market growth. For instance, in February 2022, OriGen Biomedical Inc., a global medical device manufacturer of cryopreservation, cell culture, and respiratory products, launched CryoStore FLEX Freezing Bag in the United States and Europe. The CryoStore FLEX Bag is designed for the cryopreservation of blood components and offers the multi-chamber flexibility of small-volume dose solutions.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS20619/

Competitive Landscape

The key players in the Proteomics Market are Agilent Technologies Inc., Danaher Corporation, LI-COR, Inc., PerkinElmer, Inc., Thermo Fisher Scientific, Inc., HORIBA, Ltd., Bio-Rad Laboratories, Inc., Bruker Corporation, General Electric (GE), and Waters Corporation, among others.

Recent Developments in the Proteomics Market:

• In January 2022, The Proteograph Product Suite’s Broad Commercial Release and the Centers of Excellence program’s debut were both announced by Seer, Inc. The Proteograph Product Suite offers impartial, unmatched access to the proteome. The approach uses unique designed nanoparticles to produce a ground-breaking product that enables quick, thorough, and unbiased proteomics at scale.
• In June 2021, Bruker Corp. launched the two new timsTOF instruments. It enables new methods & applications, such as epiproteomics/PTM characterization, and unbiased, and, deep multi-omic biomarker discovery.

Proteomics Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Proteomics Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Proteomics Market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Proteomics Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Proteomics Market Segmentation

By Product

• Spectroscopy
• Chromatography
• Electrophoresis
• Protein Microarrays
• Others

By Application

• Clinical Diagnostics
• Drug Discovery
• Other Application

By End-user

• Hospitals
• Clinical Laboratories
• Pharmaceutical Companies
• Academic Research Laboratories
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• Agilent Technologies Inc.
• Danaher Corporation
• LI-COR, Inc.
• PerkinElmer Inc.
• Thermo Fisher Scientific Inc.
• HORIBA Ltd.
• Bio-Rad Laboratories Inc.
• Bruker Corporation
• General Electric
• Waters Corporation

Robot as a Service (RaaS) Market to Reach US$ 59.1 Bn by 2032, driven by growing demand for professional robots in a several industries: Global Insight Services

New York, March 2022: According to a new research study by Global Insight Services (GIS), the global Robot as a Service (RaaS) Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 59.1 Billion by 2032.

Robot as a Service (RaaS) is a cloud services unit that enables the seamless integration of robots and embedded devices into online and cloud computing environments. Customers and robotic enterprises both gain from robots as a service. Robots as a service enable businesses to reap the rewards of robotic process automation (RPA) by licensing robotic gear and utilizing a cloud-based subscription service. The key advantage of employing this technology is that it reduces the need for manual IT support while increasing the efficiency of robotic procedures. The deployment of a robot as a service in an organization is dependent on three factors: first, the use of proper tools to operate the robot as a service; second, determining the precise level of services needed by the company; and third, selecting a vendor to assist the robot as a service.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10534/

The growing need for professional robots in several sectors is predicted to boost the worldwide robot as a service market expansion during the forecast period. This is due to the growing demand for automated operations across a wide range of professional fields. Due to an increase in the impact of human assistance tasks, reduction of work pressure, and support of maximum reliability in repetitive activities in industries, RaaS is gaining popularity. The RaaS market is growing due to high demand for RaaS to monitor, control, and manage other activities in the food and beverages, defense, logistics, and other manufacturing sectors. Increased automation in manufacturing facilities to boost productivity is expected to boost the growth of global RaaS market.

Robot as a Service (RaaS) Market: Restraints & Challenges

Service robots have a high annual maintenance cost, which limits firms’ ability to invest, particularly small and medium-sized businesses. This is anticipated to stifle market expansion shortly. The market’s growth is projected to be limited by organizations’ unwillingness to migrate from manual to automated operations. Companies are using RPA solutions all over the world to optimize business operations. However, a lack of understanding of the technology is preventing RaaS from being adopted. Within the next two to three years, professional service providers plan to use RPA technologies in their organization.

Robot as a Service (RaaS) Market Report Findings

https://www.globalinsightservices.com/reports/robots-as-a-service-raas-market/

The professional robots segment is likely to hold a dominant Robot as a Service (RaaS) Market share and grow at a substantial CAGR during the forecast period.

By service, the market is divided into personal and professional. The professional robots category has a bigger market share and is predicted to increase at an exponential rate throughout the forecast period. This is mostly due to increased demand for service robots in areas such as defense, construction, medical, logistics, and others.

The logistics segment is anticipated to hold a majority of the Robot as a Service (RaaS) Market size throughout the study period.

By end-user, the market is classified into healthcare, BFSI, food & beverage, IT & telecom, retail, defense, media & entertainment, logistics, and others. Because of the automation brought by the act of moving and storing goods, the logistics segment has the largest stake. In addition, there is a growing need for service robots in order to streamline supply chain procedures across sectors. Medical service robots are expected to develop significantly as people turn toward incorporating robotic solutions for important medical procedures and with the advent of high-tech research facilities.

The Europe region is estimated to exhibit the highest growth rate during the Robot as a Service (RaaS) Market forecast period.

Europe dominates the global robot as a service market, owing to increased demand for personal and professional robots in numerous nations throughout the region. Europe has the highest concentration of manufacturers, at approximately 44 percent, due to rising demand from industries such as defense, medical, logistics, and retail. Following Europe, Asia Pacific held the second-largest share and is expected to grow at the fastest rate.

This is primarily due to increased R&D activity in the industrial robot industry, as well as increased government funding in robotics, automation, artificial intelligence, and other technologies. According to World Robotics 2018, over 35% of service robot manufacturers are present in North America, raising the potential growth of the market.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10534

Competitive Landscape

The key players in the market are KUKA AG, Parrot SA, Lely International, DJI, Northrop Grumman, Intuitive Surgical, Inc., Aethon Inc., Kongberg Maritime AS, Honda Motor Co. Ltd., and iRobot Corporation., among others.

Recent Developments in the Robot as a Service (RaaS) Market:

• In July 2021, ABB purchased the ASTI Mobile Robotics Group in order to accelerate the development of flexible automation employing mobility devices. The acquisition strengthens the company’s Robotics and Machine Automation solutions, enabling it to offer a unique automation portfolio and expand into new business areas.
• In April 2021, Panasonic Corporation has released a systematic model of their Walk Training Robot, which is intended to provide effective and safe walking training for older people. In addition, the company provides a robot-assisted solution to hospitals, institutions, and other organizations.

Robot as a Service (RaaS) Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Robot as a Service (RaaS) Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Robot as a Service (RaaS) Market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Robot as a Service (RaaS) Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Robot as a Service (RaaS) Market Segmentation

By Services

• Personal
• Professional Others

By End-user

• Healthcare
• BFSI
• Food & beverage
• IT & Telecom
• Retail
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• KUKA AG
• Parrot SA
• Lely International
• DJI
• Northrop Grumman
• Intuitive Surgical, Inc.
• Aethon Inc
• Kongberg Maritime AS
• Honda Motor Co. Ltd
• iRobot Corporation

Laryngoscopes Market to Reach US$ 1.5 Bn by 2032, driven by new product launches and strategic activities by major players: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Laryngoscopes Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 1.5 Billion by 2032.

Laryngoscopy is a medical device used in the visualization and examination of larynx. It is also used during tracheal intubation in patients requiring ventilator support and compose of blades, light source and handle. The two forms of laryngoscopy procedure are direct laryngoscopy and indirect laryngoscopy.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10533

Laryngoscopes Market: Key Trends and Drivers

Increasing disease burden of laryngeal diseases as well as infectious and chronic respiratory diseases in developing countries is a major factor contributing to the laryngoscopes market share. Laryngeal cancer is second most common respiratory cancer, and incidence rate of laryngeal cancer is rising majorly due to adoption of unhealthy lifestyle and increased consumption of alcohol and tobacco. According to the Centers for Disease Control and Prevention, in U.S. about 40 million adults smoke cigarettes, and around 4.7 million middle and high school students consume at least one tobacco product. Thus, increasing adult smoking rates and tobacco consumption has led to several laryngeal diseases. Additionally, according to the American Society of Clinical Oncology (ASCO), approximately 184,615 individuals were diagnosed with laryngeal cancer globally. Hence, increasing demand for laryngoscopes to treat such diseases will accelerate the industry growth in forecast period.

Laryngoscopes Market: Restraints & Challenges

The market growth is limited by the strict regulations imposed on these devices. Additionally, high cost of these devices is another aspect that is expected to limit the industry growth. Furthermore, miniaturization of newly developed fiber optic laryngoscope could generate numerous growth opportunities for the market in the coming years.

Laryngoscopes Market Report Findings

https://www.globalinsightservices.com/reports/laryngoscopes-market/

The Video Laryngoscopes segment is likely to hold a dominant Laryngoscopes Market share and grow at a substantial CAGR during the forecast period.

Based on product, the market is bifurcated into Fiber Optic Laryngoscopes, Video Laryngoscopes, and Standard/Conventional Laryngoscopes. Video laryngoscopes segment is estimated to grow at xx% CAGR over the anticipated time period. Growing awareness about advantages associated with use of video laryngoscopes over conventional laryngoscopes will foster the market demand. The advantages include enhanced laryngeal view, reduction in applied force, and higher rates of successful rescue after the failure of direct laryngoscopy. Additionally, video laryngoscopes reduce errors during intubation and improves learning, feedback for a patient being put on ventilator.

The reusable segment is anticipated to hold a majority of the Laryngoscopes Market size throughout the study period.

Based on the usability, the market is bifurcated into Reusable, and Single-use. Laryngoscopes market from reusable segment was accounted for more than USD xx million in 2022. Reusability of devices is an important factor influencing medical professionals’ and hospitals’ purchasing decisions. These devices are highly preferred due to more functionality than traditional laryngoscopes and ease of use. On the other hand, reusable laryngoscopes, are more expensive up front but do not need to be replaced as frequently.

The hospital segment is anticipated to hold a majority of the Laryngoscopes Market size throughout the study period.

Based on the end-use, the market is bifurcated into specialty clinics, hospitals, and others. The hospital segment held over xx% revenue share in 2022, owing to expanding number of hospitals among developing and developed countries. Additionally, availability of advanced video laryngoscopes and enhanced visualization is likely to contribute to the segment demand. With high penetration of hospitals and presence of healthcare professionals will bolster the laryngoscopes market progression.

The Europe region is estimated to exhibit the highest growth rate during the Laryngoscopes Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Europe laryngoscopes market exceeded USD xx million in 2022 and is predicted to witness enormous growth during analysis timeframe due to rising prevalence of respiratory diseases among geriatric population as well as in adults. Increasing consumption of tobacco, smoking and rising air pollution are some factors that trigger respiratory diseases. Moreover, increasing number of healthcare initiatives by several government and non-government organization in the region will accelerate the regional market growth.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10533

Competitive Landscape

The global Laryngoscopes Market report includes players are KARL STORZ GmbH & Co, Ambu A/S, Medtronic plc, Flexicare Medical, Penlon Limited, Rudolf Riester GmbH, Propper Manufacturing Co. Inc., Teleflex Incorporated, Verathon Inc, Venner Medical, Olympus Corporation, among others.

Recent Developments in the Blood-Brain Barrier Market:

• In November 2022, PROACT Medical launched an innovative new range of gas sampling lines along with their new line of single-use laryngoscopes in the European market.
• In July 2022, Zsquare, a leading developer of high-performance, single-use endoscopes, announced that it received FDA clearance to market its first product, the Zsquare ENT-Flex Rhinolaryngoscope.

Laryngoscopes Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Laryngoscopes Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Laryngoscopes Market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Laryngoscopes Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Laryngoscopes Market Segmentation

By Product

• Fiber Optic Laryngoscopes
• Video Laryngoscopes
• Standard/Conventional Laryngoscopes

By Usability

• Reusable
• Single-use

By End-use

• Hospitals
• Specialty Clinics
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• KARL STORZ GmbH & Co
• Ambu A/S
• Medtronic plc
• Flexicare Medical
• Penlon Limited
• Dodow (LIVLAB)
• Rudolf Riester GmbH
• Propper Manufacturing Co. Inc
• Teleflex Incorporated
• Verathon Inc,

Sleep Tech Devices Market to Reach US$ 95.8 Bn by 2032, driven by high prevalence of sleep disorders is expected to increase the demand for sleep tech devices: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Sleep Tech Devices Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 95.8 Billion by 2032.

Sleep tech devices are designed for monitoring and improving the outcome in patients with sleep disorders such as sleep apnea, insomnia, narcolepsy, etc.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10532/

Sleep Tech Devices Market: Key Trends and Drivers

Increasing technological advancements in sleep trackers is one of the significant opportunities for the sleep tech devices market growth. Sleep trackers are becoming more sophisticated. For example, 2breathe is a smart device that is supposed to be worn around the waist before going to bed. The device can detect breathing and play tones to aid sleep, and it automatically shuts off when it detects snoozing. It’s linked to an app that shows how one slept every morning. Beddit, on the other hand, is a sleep sensor that consists of a thin rectangle that is placed beneath sleeper sheets. It then monitors a variety of parameters, including sleep, varying sleep stages, respiration rate, heart rate, and more.

Sleep Tech Devices Market: Restraints & Challenges

the market growth is limited by the strict regulations imposed on these devices. Additionally, high cost of these devices is another aspect that is expected to limit the industry growth. Furthermore, miniaturization of newly developed sleep trackers could generate numerous growth opportunities for the market in the coming years.

Sleep Tech Devices Market Report Findings

https://www.globalinsightservices.com/reports/sleep-tech-devices-market/

The non-wearables segment is likely to hold a dominant Sleep Tech Devices Market share and grow at a substantial CAGR during the forecast period.

Based on product, the market is bifurcated into wearables, and non-wearables. Sleep tech devices market from non-wearables segment accounted for xx% business share in 2022 and is set to register a significant CAGR through 2032 driven by growing demand for smart beds. This smart bed can monitor and modify its settings automatically to help sleep soundly all night. It adapts to one sleeping position in real time, gently conforming to side, back, or stomach profiles to make sleeping comfortable. The bed can also help fall asleep faster by warming feet.

The narcolepsy segment is anticipated to hold a majority of the Sleep Tech Devices Market size throughout the study period.

Based on the application, the market is bifurcated into insomnia, obstructive sleep apnea, narcolepsy, and others. Sleep tech devices market from narcolepsy segment held nearly xx% revenue share in 2022. This is owing to the growing cases of narcolepsy. Narcolepsy is a chronic sleep condition that usually begins in adolescence and is characterized by extreme daytime sleepiness with serious repercussions for the patient. According to Journal of Clinical Sleep Medicine the cases of narcolepsy per 100,000 population increased by 14%, i.e., from 38.9 in 2013 to 44.3 in 2016. Such factors are expected to facilitate the demand for sleep tech devices and medication.

The specialty centers segment is anticipated to hold a majority of the Sleep Tech Devices Market size throughout the study period.

Based on the distribution channel, the market is bifurcated into specialty clinics, direct-to-consumer, hospitals, and others. Sleep tech devices market from specialty centers segment will exhibit a CAGR of xx% during the forecast period. The demand for sleep tech devices has surged as the number of patients suffering from sleeping problems has also increased. Sleep difficulties are common among people with psychological illnesses, and often prefer to seek therapy at specialty clinics. Sleep tech devices, such as sleep trackers, are recommended by healthcare professionals working in specialist clinics to boost mental health in individuals. The segment is also likely to rise as people become more aware of sleep therapy sessions.

The Europe region is estimated to exhibit the highest growth rate during the Sleep Tech Devices Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the Europe market accounted for the largest revenue share in the global market in 2022. Rising prevalence of sleep disorders in the region, owing to an ageing population and rising cases of depression and insomnia among adults. For instance, according to an NHS Inform research, roughly one in every three persons in the UK suffers with insomnia, that is especially prevalent among the elderly population. Furthermore, high disposable income and presence of leading industry players in the region contributes significantly to the regional business growth..

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10532/

Competitive Landscape

The global Sleep Tech Devices Market report includes players are Casper Sleep Inc., Cadwell Industries Inc., Dreem, Beddit (Apple Inc.), Eight Sleep, Dodow (LIVLAB), Emfit Ltd., Fitbit Inc. (Google LLC), ResMed Inc., Koninklijke Philips N.V., Sleep Shepherd LLC, Oura Health Ltd., Sleepace, Xiaomi, Withings,, among others.

Recent Developments in the Blood-Brain Barrier Market:

• In May 2022, Huawei Vietnam launched three new generation smartwatches, Huawei Watch GT3 Pro, Watch fit 2 and Watch Kids 4 Pro. This smartwatch is equipped with advanced features such as health alerts, early sleep alerts, medication alerts, and positive mood and exercise volume information.
• In February 2022, Redmi launched the Redmi Smart Band Pro equipped with features such as an AMOLED display and 50 meters of water resistance. In addition, it has a heart rate monitor and a SpO2 sensor that will enable blood oxygen monitoring and sleep monitoring..

Sleep Tech Devices Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Sleep Tech Devices Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Sleep Tech Devices Market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Sleep Tech Devices Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Sleep Tech Devices Market Segmentation

By Product

• Wearables
• Non-Wearables

By Application

• Insomnia
• Obstructive Sleep Apnea
• Narcolepsy
• Others

By Distribution Channel

• Specialty Clinics
• Direct-to-Consumer
• Hospitals
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• Casper Sleep Inc
• Cadwell Industries Inc.
• Dreem
• Beddit (Apple Inc.)
• Eight Sleep
• Dodow (LIVLAB)
• Emfit Ltd.
• Fitbit Inc. (Google LLC)
• ResMed Inc.
• Koninklijke Philips N.V.

Medical Equipment Financing Market to Reach US$ 311.9 Bn by 2032, driven by rapid technological advancements combined with AI technology has leveraged the medical industry potential: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Medical Equipment Financing Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 311.9 Billion by 2032.

The need of time is staying up to date with advancements in medical equipment but it can be an expensive prospect. That’s why many health care professionals need medical equipment financing to obtain the tools and machines they need. A medical equipment loan or lease helps those professionals get the equipment they need to bring in new and returning patients, helping them increase cash flow and build their reserves. With the continuous advancement in medical technology, it has become a necessity to opt for the best-in-class medical equipment for excellent healthcare services. However, advanced diagnostic systems are expensive and are difficult for medical practitioners and hospitals to afford through their funds. There arises the need for medical equipment funding with low monthly instalments and flexible loan models.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10531/

Medical Equipment Financing Market: Key Trends and Drivers

Increasing acceptance of artificial intelligent technology has leveraged the medical industry potential. With this, there is an upgradation to new equipment with better features that provides superior treatment to the patients. For instance, according to the Equipment Leasing & Finance Foundation’s Report, in 2019, nearly 8 in 10 businesses that acquired equipment and software used at least one form of financing such as lease, secure loan, or line of credit. Therefore, acquiring medical equipment with medical equipment loans and leases has been made simple and easy.

Medical Equipment Financing Market: Restraints & Challenges

As their economies expand, equipment finance firms continue to face numerous challenges. Even while banks have more resources and are seeking chances in the medical equipment market, the majority of businesses have grown more capital-conscious. It is more likely that hospitals, clinics, and diagnostic centers will spend money to maintain their existing equipment than to purchase new ones..

Medical Equipment Financing Market Report Findings

https://www.globalinsightservices.com/reports/medical-equipment-financing-market/

The patient monitoring equipment segment is likely to hold a dominant Medical Equipment Financing Market share and grow at a substantial CAGR during the forecast period.

Based on equipment, the market is bifurcated into diagnostics equipment, therapeutic equipment, patient monitoring equipment, laboratory equipment, and medical furniture. Among these, the patient monitoring equipment segment exceeded USD xx billion in 2022. This is attributed to the increasing demand for patient monitoring equipment in developing countries to observe, report and analyze acute or chronic conditions used in hospitals and clinics. Additionally, increasing use of ECG devices to check heart’s rhythm and electrical activity will propel overall medical equipment financing market expansion. Furthermore, high availability of patient monitoring equipment in the market such as blood pressure monitors, electro-cardiograph (ECG) device, patient monitors, pulse oximeter, pulse watches, continuous glucose monitoring device, spirometers, and capnography, among others. This will fuel the market progression. Therefore, many firms incline towards medical equipment financing & leasing, and loans required for infrastructure.

The new medical equipment segment is anticipated to hold a majority of the Medical Equipment Financing Market size throughout the study period.

Based on the type, the market is bifurcated into new medical equipment, rental equipment, and refurbished equipment. Among these, new medical equipment segment surpassed USD xx billion in 2022. This is owing to adoption of artificial intelligence, blockchain, voice search, chatbots, and virtual reality in health technologies. Moreover, increasing costs of the medical equipment’s, leading doctors or healthcare firms incline towards loan to purchase an equipment, this also reduces the high interest rates regardless of any type and number of instruments. In addition, it also helps in preserving working capital and streamline operations in a modified manner. Therefore, growing adoption of new medical equipment will foster the overall market size.

The Hospital segment is anticipated to hold a majority of the Medical Equipment Financing Market size throughout the study period.

Based on the end-user, the market is bifurcated into hospitals, clinics, laboratories & diagnostic centers, and ambulatory surgical centers [ASCs]. Medical equipment financing market from hospital segment accounted for xx% business share in 2022 and is set to register a significant CAGR through 2032. This is due to the rising utilization of medical equipment financing practices that allows hospitals to purchase medical equipment at lower price. Similarly, equipment financing increases the working capital of hospitals with more available capital. This allows hospitals in hiring new doctors and clinicians along with investment in cybersecurity software. Moreover, hospitals prefer to opt for healthcare loan including infrastructure loan and working capital to avoid risks in the market. Thus, medical equipment financing reduces the risk and controls the overall financial situations. As a result, increased hospital investments around the globe will certainly have a positive impact on the industry growth.

The North America region is estimated to exhibit the highest growth rate during the Medical Equipment Financing Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the Europe medical equipment financing market is expected to grow at xx% CAGR during the forecast period driven by the high cost of healthcare equipment. According to the Organization for Economic Co-operation and Development (OECD), in Europe, the healthcare spending per capita increased around 3% each year between 2013 and 2019 by adjusting the inflation. Similarly, growing demand for medical equipment financing coupled with presence of major market player including Meridian Group International, and Societe Generale S.A will accelerate the regional market trends..

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10531/

Competitive Landscape

The global Medical Equipment Financing Market report includes players are CMS Funding, Kabbage (American Express), Bajaj Finserv, TIAA Bank, Blue Bridge Financial, LLC, First American Healthcare Finance, HDFC Bank, HeroFinCorp, JPMorgan Chase & Co., National Funding, SMC Finance, Truist Bank, Societe Generale S.A., and Toronto-Dominion Bank., among others.

Recent Developments in the Market:

• In February 2022, Toronto-Dominion Bank and First Horizon announced the signing of a new contract that will allow Toronto-Dominion Bank to completely acquire First Horizon. The deal is worth USD 13 billion and will help TD strengthen its hold in the global market
• In December 2021, API Holdings Limited and Piramal Capital & Housing Finance entered a joint collaboration in which the latter will offer its digital platform Retailio to API Holding. This will allow the company to improve its financial assistance services to all stakeholders.
• In July 2021, IFC and the Multilateral Investment Guarantee Agency (MIGA) launched a trade finance guarantee initiative to help low-income countries recover from the effects of the pandemic by supporting trade flows of critical goods, including food and medical equipment.
• In May 2021, E. Healthcare and NSIA Banque Cote d’Ivoire announced a partnership with IFC’s Africa Medical Equipment Facility to strengthen the healthcare industry and support medical equipment financing across Africa.
• In April 2021, IMAGEENS jointly raised $1.45 million in seed funding with Anaxago. This is expected to strengthen the company’s team with key R&D talent to expand the deployment of software solutions.

Medical Equipment Financing Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Medical Equipment Financing Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Medical Equipment Financing Market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Medical Equipment Financing Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Medical Equipment Financing Market Segmentation

By Equipment

• Laboratory Equipment
• Therapeutic Equipment
• Diagnostics Equipment
• Patient Monitoring Equipment
• Medical Furniture

By Type

• Refurbished Equipment
• Rental Equipment
• New Medical Equipment

By End-usee

• Hospital
• Clinics
• Laborateries &Diagnostic Centers
• Ambulatory Surgical Centers [ASCs]

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• CMS Funding
• Kabbage (American Express)
•  Bajaj Finserv
• TIAA Bank
• Blue Bridge Financial, LLC
• First American Healthcare Finance
• HDFC Bank
• HeroFinCorp
• JPMorgan Chase & Co.
• National Funding
• SMC Finance

Compartment Syndrome Monitoring Devices Market to Reach US$ 409.7 Million by 2032, driven by increasing investments in research-based projects and growing alliances among leading companies and research centers for drug discovery, and increasing inclination toward next-generation sequencing methods for identifying, treating, and monitoring chronic diseases: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Compartment Syndrome Monitoring Devices Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 409.7 Million by 2032.

The compartment syndrome monitoring devices refer to medical equipment that is employed for monitoring the compartmental pressure that assists in detection of compartment syndrome. These devices are specialized equipment that are increasingly employed in monitoring acute, chronic, and abdominal compartment syndrome.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10530/

Compartment Syndrome Monitoring Devices Market: Key Trends and Drivers

Technological developments in compartment pressure monitoring devices and the advent of a collaborative technique for promoting the operationality & precision of these devices will foster the business landscape. Better understanding of the pathophysiology of compartment syndrome and notable developments in compartment syndrome monitoring devices have improved the diagnosis of compartment syndrome & is expected to reduce the disease morbidity. The application of innovative diagnostic modalities including near-infrared spectroscopy (NIRS), radiofrequency identification (RFID) implants, and biomarker analysis is estimated to fuel the user preference.

The emergence of RFID implants, a novel technology that employs radio frequency electromagnetic waves for transferring data would assist the clinicians. Hence, the RFID sensors are in demand and being used in compartment syndrome monitoring devices. Furthermore, the product development and commercialization by major market players is set to prove beneficial for market growth.

Compartment Syndrome Monitoring Devices Market: Restraints & Challenges

Some of the market obstacles include a scarcity of experienced specialists and significant investment costs, as well as legal and ethical concerns about the market methods and outcomes in numerous nations.

Compartment Syndrome Monitoring Devices Market Report Findings

https://www.globalinsightservices.com/reports/compartment-syndrome-monitoring-devices-market/

The disposable segment is likely to hold a dominant Compartment Syndrome Monitoring Devices Market share and grow at a substantial CAGR during the forecast period.

Based on Product, the market is bifurcated into Disposables, and Equipment. Disposables segment is anticipated to witness xx% CAGR from 2022 to 2032 due to the rising preference for single-use and disposable equipment. Disposable medical supplies lower the risk concerned with hospital-acquired infection (HAI) by delivering better protection against transmission and contamination. The increasing usage and surged demand for sustainable medical solutions will stimulate the market share.

The Chronic compartment syndrome segment is anticipated to hold a majority of the Compartment Syndrome Monitoring Devices Market size throughout the study period.

Based on the syndrome type, the market is bifurcated into Acute Compartment Syndrome, Chronic Compartment Syndrome, and Abdominal Compartment Syndrome. Chronic compartment syndrome segment surpassed USD xx million in 2022 and is likely to register xx% CAGR from 2022 to 2032. This is owing to the substantial prevalence of chronic compartment syndrome. This is also known as chronic exertional compartment syndrome (CECS) that refers to a condition that majorly occurs due to exertional or repetitive loading activities. CECS is commonly profound among athletes such as long-distance runners, football players, skiers, and basketball players.

The Clinics segment is anticipated to hold a majority of the Compartment Syndrome Monitoring Devices Market size throughout the study period.

Based on the end-use, the market is bifurcated into Hospitals, Clinics, and Others. Clinics segment accounted for xx% revenue share in 2022 and is projected to progress at % CAGR during the forecast period. This is pertaining to the surging preference and steady transition towards clinics. The demand for these healthcare settings is surging with high application rate of novel compartment syndrome monitoring devices. Furthermore, the shift in the preference towards clinics due to several advantages including rapid assistance and cost-effective services have substantially impacted the segment growth. Clinics are regarded as a preferable alternative for preventive care and effective management of chronic conditions as they feature low waiting periods.

The North America region is estimated to exhibit the highest growth rate during the Compartment Syndrome Monitoring Devices Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the North America market accounted for the largest revenue share in the global market in 2022. North America has a large regional market in terms of revenue. The increasing prevalence of genetic and chronic disorders, such as cancer, the aging population, the growing demand for targeted and personalized medicine, and favorable government initiatives are the primary factors behind the growth of the whole-exome sequencing market. According to the HIV.gov updates in October 2022, HIV affects around 1.2 million persons in the United States. In the United States, in 2020, 30,635 persons were diagnosed with HIV. Thus, the growing burden of infectious diseases is expected to increase in demand for its diagnosis, thereby boosting the market’s growth over the forecast period.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10530/

Competitive Landscape

Some of the major players operating in the compartment syndrome monitoring devices industry are Millar, Inc., MY01, Inc., Critical Care Diagnostics (C2DX), Inc., Potrero Medical, Medline Industries, Becton, Dickenson, and Company, and ConvaTec. These players are involved in mergers & acquisitions, partnerships, and distribution agreements to gain competitive advantage over their competitors.

Recent Developments in the Blood-Brain Barrier Market:

• In September 2022: Potrero Medical received FDA Breakthrough Device Designation for their AKI Predict machine learning algorithm, for the advanced prediction of acute kidney injury (AKI) associated with IAH in cardiac post-surgical intensive care patients.
• In July 2022: Sentinel Medical Technologies launched TraumaGuard Monitoring Device, a hands-free monitoring device designed to continuously measure real-time IIP and Core Body Temperature (CBT) in critical care patients.
• In March 2022, C2Dx, another industry leader, announced the acquisition of Hemostatix Medical Technologies LLC, a medical device specialist. The acquisition complemented C2Dx’s plans to enhance the delivery of niche medical products around the world.

Compartment Syndrome Monitoring Devices Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Compartment Syndrome Monitoring Devices Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Compartment Syndrome Monitoring Devices Market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Compartment Syndrome Monitoring Devices Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Compartment Syndrome Monitoring Devices Market Segmentation

By Product

• Disposables
• Equipment

By Technology

• Acute Compartment Syndrome
• Chronic Compartment Syndrome
• Abdominal Compartment Syndrome

By Application

• Hospitals
• Clinics
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• Millar, Inc.
• MY01, Inc.
• Critical Care Diagnostics (C2DX), Inc.
• Potrero Medical
• Medline Industries
• Boston Scientific Corporation
• Becton, Dickenson, and Company
• ConvaTec.
• Hemostatix Medical Technologies LLC,
• Biometrix Ltd. (3i Group plc)

Hemostasis Products Market to Reach US$ 2.7 Bn by 2032, driven by increase in number of surgeries such as orthopedic surgery, gynecological surgery, reconstructive surgery, and cardiac surgery; rise in in various cancer types that require surgical procedures; and development of new hemostasis product market by large number of key players: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Hemostasis Products Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 2.7 Billion by 2032.

Hemostat is referred to a surgical agent that regulates and controls the bleeding process during surgical procedures. Hemostats help to shorten surgery time and reduces the need for blood transfusion. Hemostatic agents are essential in establishing hemostasis in pre-hospital conditions and preventing death associated with hemorrhage. Hemostats are used to compress blood vessels and prevent the flow of blood or other fluids. They are generally used in adjunct to surgical procedures to manage bleeding. Hemostatic agents offer different benefits, which include decreased wound healing & operative time, better management of anti-coagulated patients, and reduction in the patient recovery period boosting the hemostasis market.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10529/

Hemostasis Products Market: Key Trends and Drivers

Rise in flowable hemostats usage boosts the flowable hemostats market. According to the International Osteoporosis Foundation, in 2019, approximately 200 million people were affected by osteoporosis-related fractures across the globe. Thus, rise in burden of orthopedic disorders increases the demand for hemostats to reduce surgical injuries, which is anticipated to foster the growth of the hemostats market size. Furthermore, rise in geriatric population notably contributes toward the growth of the market. This is attributed to the fact that aged individuals are highly susceptible to various types of diseases, which increases the need for surgeries, thus boosting the hemostats market share. Furthermore, increase in number of road accidents has led to surge in surgical procedures, which augmented the growth of the hemostats market. According to the World Health Organization, in 2019, approximately 235 million major surgical procedures were performed across the globe. According to the National Cancer Statistics, in 2020, there were 1,806,590 new cases of cancer in the U.S. Therefore, surge in number of surgeries is anticipated to boost the growth of the market. According to the American Society of Plastic Surgeons, 15.6 million cosmetic surgeries were performed in 2020. Furthermore, increase in number of product approvals is expected to provide lucrative hemostats market opportunity for the expansion during the hemostats market forecast period. Thus, rise in hemostats utilization in surgeries is bound to increase hemostasis market potential.

Hemostasis Products Market: Restraints & Challenges

Some of the market obstacles include a scarcity of experienced specialists and significant investment costs, as well as legal and ethical concerns about the market methods and outcomes in numerous nations.

Hemostasis Products Market Report Findings

https://www.globalinsightservices.com/reports/hemostasis-products-market/

The Infusible hemostasis products segment is likely to hold a dominant Hemostasis Products Market share and grow at a substantial CAGR during the forecast period.

Based on Product, the market is bifurcated into Topical Hemostasis Product, Infusible Hemostasis Product, and Advanced Hemostasis Product. Infusible hemostasis products segment surpassed USD xx million in 2021. This is attributable to the growing number of patients suffering from cardiac diseases such as myocardial infarction, coronary heart disease, aortic disease etc. Cardiovascular disease is responsible for majority of deaths in countries such as India. It accounts for more than 25% of total deaths occurring in the country. Thereby, stimulating the product demand.

The Hemostat agents segment is anticipated to hold a majority of the Hemostasis Products Market size throughout the study period.

Based on the application, the market is bifurcated into Trauma, Surgery, Hemophilia, Myocardial Infarction, Thrombosis, and Others. Hemostat agents, such as products containing thrombin, are a safe and effective alternative to gelatin sponges and oxidized cellulose in controlling bleeding during surgeries. Hemostatic agents containing thrombin and collagen are superior to surgical hemostasis alone in controlling microvascular bleeding during cardiac surgery. It is also reasonable to use fibrin sealants as an adjunct to surgical hemostasis to limit bleeding in cardiac and aortic surgery.

As per the research study published in June 2021, titled “German Heart Surgery Report 2020: The Annual Updated Registry of the German Society for Thoracic and Cardiovascular Surgery”, a total of 92,809 operations were classified as heart surgery procedures in the classical sense, of which 29,444 were isolated coronary artery bypass grafting procedures, 35,469 were isolated heart valve procedures, and the number of isolated heart transplantations increased by 2% to 340. Additionally, according to the British Heart Foundation’s February 2021 report, about 371,000 heart procedures and operations were performed in England in 2020. Hence, the high number of heart surgeries and operations being performed every year may boost demand for hemostat agents that control bleeding.

The Hospitals segment is anticipated to hold a majority of the Hemostasis Products Market size throughout the study period.

Based on the end-use, the market is bifurcated into Hospitals, Clinics, and Others. The increase in hospital visits and growing expenditures on hospital care can be attributed to the growth of the hospital segment. Hospital spending climbed 6.4% amounting to USD 1,270.1 billion in 2020, the National Health expenditure data sheet states. This was an increase from the 6.3% growth in 2019. Additionally, there were almost 130 million hospital visits in the United States. Few of the well-known market leaders in the global hemostasis products market that are profiled by Research Nester are Pfizer Inc., Integra LifeSciences Corporation, Baxter, Medtronic, Stryker, BD (Becton, Dickinson and Company), Biom’up Innovative Surgery, Johnson & Johnson Services, Inc., CryoLife, Inc., Hemostatis LLC, and others.

The Asia Pacific region is estimated to exhibit the highest growth rate during the Hemostasis Products Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the market growth in Asia Pacific is elevated by rising instances of road accidents followed by rise in blood donations in the region. According to the Ministry of Road Transport & Highways under Government of India, in 2022, the country witnessed 3,66,138 road accidents, leading to 1,31,714 losses of lives and 3,48,279 people injured. 18-45 years’ age group is the prime group caught up in road accidents, which accounts for nearly 70% of total accidental deaths. Furthermore, in Japan, 400 mL blood donations are expected to result in an estimated 1.3 million liters of blood being donated in 2020. Additionally, from 1998 to 2020, blood donation increases by 40 folds in China and in 2020, there were approximately 16 million blood donation in the country.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10529

Competitive Landscape

The global hemostasis products market is moderately fragmented and consists of a number of major players. Companies like Abbott Laboratories, Baxter International, Inc., C. R. Bard, Inc. (BD), CSL Behring LLC, Dexur, Grifols, S.A., Johnson & Johnson, Medtronic plc, Pfizer, Inc., and Tricol Biomedical, among others, hold the substantial market share in the Hemostasis Products market.

Recent Developments in the Blood-Brain Barrier Market:

• In May 2022, Precision BioLogic Inc., a developer of hemostasis diagnostic products, reported the launch of its new cryocheck Chromogenic Factor IX assay in Canada, the European Union, and the United Kingdom, Australia, and New Zealand.
• In February 2022, Futura Surgicare Pvt Ltd expanded its product portfolio by launching hemostatic products under the brand Hemostax (Oxidised Regenerated Cellulose) under a new vertical, Dolphin Hemostats. Hemostax Standard is an absorbable hemostat designed to help surgeons control bleeding more efficiently.

Hemostasis Products Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Hemostasis Products Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Hemostasis Products Market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Hemostasis Products Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Hemostasis Products Market Segmentation

By Product

• Topical Hemostasis Product
• Infusible Hemostasis Product
• Advanced Hemostasis Product

By Technology

• Trauma
• Surgery
• Hemophilia
• Myocardial Infarction
• Thrombosis
• Others

By Application

• Hospitals
• Clinics
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• Abbott Laboratories
• Baxter International, Inc.
• C. R. Bard, Inc. (BD)
• CSL Behring LLC
• Dexur
• Boston Scientific Corporation
• Grifols, S.A.
• OraSure Technologies, Inc.
• Johnson & Johnson
• Medtronic plc
• Pfizer, Inc.
• Tricol Biomedical

pH Meters Market to Reach US$ 2.4 Bn by 2032, driven by Rising demand for these devices in industries such as food processing, water treatment, power, agriculture, fertilizers, etc.: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global PH Meters Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 2.4 Billion by 2032.

pH meters are instruments that are used to measure hydrogen-ion activity to determine acidic and alkaline levels in solutions. They are calibrated with known pH levels of solutions before use to ensure the accuracy and precision of results. They are used to ensure acidic levels in various applications ranging from water treatments to laboratories.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10527

PH Meters Market: Key Trends and Drivers

Growing incidences of microbial infections coupled with technological advancements in pH meters are expected to serve as lucrative growth opportunities for this market. Moreover, the increasing number of research and testing laboratories such as soil testing, water testing, and food testing laboratories is also one of the factors, expected to boost the usage of these devices.

PH Meters Market: Restraints & Challenges

Many pH meters are soluble only in low conductivity solutions especially in distilled, deionized and ultrapure water. Continuous drift, frequent calibration and short service life will result from pH glass dissolution. The dissolving process will only accelerate at elevated temperature. There are no data available for selecting the right electrode, trial and error will provide the answer such uncertainties may hamper the market.

PH Meters Market Report Findings

https://www.globalinsightservices.com/reports/ph-meter-market/

The bench top pH meters segment is likely to hold a dominant PH Meters Market share and grow at a substantial CAGR during the forecast period.

By product type, the market is segmented into benchtop, and portable pH meters. Technological advancements such as online pH meters, calibration-free measurement systems, microprocessors for auto temperature, and pressure compensation are few of the factors that are expected to propel the market growth over the next seven years. In 2022, bench top pH meters held over xx% of the overall pH meters market owing to, its wide application in academic institutes, laboratories, industrial researchers, ease of usage, and growing demand for easy accessibility and accuracy. Portable pH meters are expected to witness a lucrative growth of over 7% during the forecast period of seven years. High mobility and small size of these meters is one of the key factors attributing to its rapid growth. Stringent regulations on water treatment plants by various EPA (Environmental Protection Agency), rising health concern among the population regarding adverse effect of quality of water and easy accessibility & availability of such instruments are among few of the factors that are expected to boost the usage of pH meters across various industries.

The manual type segment is anticipated to hold a majority of the PH Meters Market size throughout the study period.

By type, the pH meters market is segmented into digital and manual type pH meter. The manual type of pH meter segment has accounted for around USD xx million in 2022. This is owing to increasing adoption of manual pH meters as these types are mainly used in food and beverages and pharmaceutical industry to measures acidity/alkalinity of a solution. pH meters are also used to measure the acidity for preserving foods and fermentation process and it gives better operational control. Therefore, the demand for manual pH meters will boost.

The food and beverages segment is anticipated to hold a majority of the PH Meters Market size throughout the study period.

Based on end-use, the market is categorized into pharmaceutical and biotechnology companies, food and beverages, environmental testing, government and academic institutions, chemicals and petrochemicals, water, and wastewater treatment and others. Among these, the food and beverages segment are projected to witness xx% CAGR from 2022 to 2032. The demand for measuring pH meters in food and beverages industry for maintaining quality, safety, and consistency in food and beverages is increasing annually. Measuring pH value is one of the parameters measured during an inspection of the product before release. For instance, during cheeses-making, enzymatic activity is highly dependent on pH for improving yield and enhancing flavor.

Additionally, controlling pH regulates the growth of desirable and non-desirable microorganisms. Thus, to maintain different types of food such as acidified food, fermented food, and low-acid canned food, resulting in an increase in demand for pH meter thereby, driving the overall market statistics.

The North America region is estimated to exhibit the highest growth rate during the PH Meters Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the Europe pH meters market is expected to grow at xx% CAGR over the forecast period. The regional growth is attributable to the technological advancement integrated within the pH meter and rising regulatory landscape in developed as well as developing countries. Further, increasing incidences of water borne diseases will spur the regional market statistics. For instance, according to the European Centre for Disease Prevention and Control (ECDC), in 2018, Europe countries reported 26 confirmed cases of cholera.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10527

Competitive Landscape

Some of the prominent industry players operating in the pH meters industry include Thermo Fisher Scientific, Contech Instruments, Emerson Electric Co. (Rosemount Analytical), Hach, Qingdao Tlead International, Hamilton Company, PCE Instruments, Hanna Instruments, Inc., Panomex Inc., Shanghai Selon Scientific Instrument Co., Ltd., Horiba, Jenco Instruments Inc., Metrohm AG, TECPEL CO., LTD., Agilent Technologies, and Mettler-Toledo International Inc., among others.

Recent Developments in the Blood-Brain Barrier Market:

• In March 2020, Metrohm AG launched new handheld 913 pH/DO Meter. This pH meter can measure pH value and concentration of dissolved oxygen within the same sample.
• In 2017, Mettler Toledo, one of the leading global precision instruments manufacturer, launched Pro2Go, a smart handheld PH meter. The portable PH meter provides accurate and fast measurement, single-handed operational capabilities, and great durability.

PH Meters Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global PH Meters Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future PH Meters Market potential from 2022 to 2032 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the PH Meters Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global PH Meters Market Segmentation

By Product

• Bench top pH Meters
• Portable pH Metersystem

By Type

• Digital
• Manual

By End-use

• Pharmaceutical and Biotechnology Companies
• Food and Beverage
• Environmental Testing
• Government and Academic Institutions
• Chemicals and Petrochemicals
• Water and Wastewater Treatment
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• Thermo Fisher Scientific
• Contech Instruments
• Emerson Electric Co. (Rosemount Analytical)
• Hach
• Qingdao Tlead International
• Hamilton Company
• QIAGEN
• PCE Instruments
• Hanna Instruments, Inc.
• Panomex Inc

Biodefense Market to Reach US$ 40.7 Bn by 2032, driven by rising demand for better flexibility in Service Level Agreements (SLAs) and convenience in change management procedures together with cost-cutting: Global Insight Services

New York, March 2022: According to a new research study by Global Insight Services (GIS), the global Biodefense Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 40.7 Billion by 2032.

Biodefense can be defined as the activity of preparing for, responding to and countering the acts of bioterrorism. A bioterrorism attack involves the deliberate release of bacteria, viruses and other pathogens that can cause chronic illnesses to humans, animals, agriculture and the environment. Biodefense involves various medical measures that are undertaken to protect individuals against biological threats, such as administering vaccinations and medicinal drugs, along with conducting research and various public health procedures. Biodefense products are commonly effective against anthrax, smallpox, botulism, radiation/nuclear disasters and other such catastrophes..

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10528

Biodefense Market: Key Trends and Drivers

Growing investments by government will augment the overall market progression

Growing investments by government in R&D that encourages pharmaceutical and biopharmaceutical companies to boost the production of vaccines will propel the biodefense market share. Increasing global biological threats has created need for funds to support the R&D activities. Government authorities’ stock large amounts of vaccines and bio-threat detection devices to combat against the deliberate virus attacks. For instance, as per the FDA FY 2023 budget, investment of USD 1.6 billion over five years has been allocated for biodefence vaccines and development of biodefense diagnostic devices. Therefore, growing investments in biodefense enables biopharmaceutical companies to manufacture technologically advanced biothreat detection devices that will significantly drive the industry outlook.

Biodefense Market: Restraints & Challenges

KPO industry faces challenges like shortage of manpower and knowledge issues concerns for data security and poor infrastructure, and rise in real-state costs. All of these factors combined tend to be huge challenges for the industry to grow and prosper. For example, the KPO industry requires professionals with the right skill-sets and domain knowledge but there’s a shortage of such professionals especially in developing economies.

Biodefense Market Report Findings

https://www.globalinsightservices.com/reports/biodefense-market/

The anthrax segment is likely to hold a dominant Biodefense Market share and grow at a substantial CAGR during the forecast period.

By product, the biodefense market is segmented into anthrax, botulism, smallpox, radiation/nuclear, and other products. The anthrax segment held the largest market share of xx% in 2022 and is expected to grow at a significant CAGR over the forecast period. Based on products, the market is segmented into anthrax, smallpox, botulism, radiation/ nuclear, and others. Bacillus anthracis is a gram-positive bacterium that causes anthrax. It is one of the most likely to be used potential weapons for a bioterrorist attack. These spores are mostly preferred as they can be easily released into the environment by placing them in food, water, powder, and sprays.

They can last for a long time in the environment and are easily found in nature (soil, plants, or water). According to NCBI, anthrax bacteria is categorized as a tier-1 biological agent as it can be easily transmitted from one person to another and holds the potential for a major public health tragedy. Countermeasures against anthrax remain one of the key areas for countermeasures. It has received major funding for vaccine development. This includes project bioshield, which has witnessed over USD 50 billion in funding since the September 11 attack in the United States. Many companies have their vaccine for anthrax in clinical trials.

The other product segment is expected to be the fastest-growing segment with a 6.2% CAGR over the forecast period. It includes viruses like include viral hemorrhagic fever, brucellosis, cholera, influenza, plague, food poisoning, tularemia, Zika, Ebola, and many others. The National Institute of Allergy and Infectious Diseases (NIAID) has a Vaccine Research Centre (VRC), which is working on VHF vaccines since 2003, especially against Ebola and Marburg viruses. The University of Texas at San Antonio (UTSA) has been awarded a contract from the U.S. Department of Defense (DoD) to develop a vaccine against tularemia. Tularemia being highly infectious and at times fatal in nature is a potential option for a bioweapon. Recently many countries are witnessing rising infection cases due to the zika and ebola viruses and therefore many companies are competing to develop its vaccine. MVA-BN Filo, manufactured by Bavarian Nordic, is a vaccine against two filoviruses, Ebola, and Marburg’s diseases, and is currently under phase 3 clinical trials and has collaborated with the U.S. NIAID for the same.

The Asia-Pacific region is estimated to exhibit the highest growth rate during the Biodefense Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the Biodefense market capturing an xx% market share in 2022 and is expected to showcase a significant CAGR in the forecast period. This is attributed to the presence of high federal funding, technological advancements, and growing awareness among the population. The presence of major players in this region is also a favorable prospect for the biodefense market in 2022. Based on Federal Research and Development (R&D) in the fiscal year 2017, out of the total federal R&D funding that was received by eight federal agencies, 96.3% of it was received by the Department of Defense (39.3%) and the Department of Health and Human Services (27.3%) combined accounting for more than two-thirds of all federal R&D funding. This percentage of funding to DoD is proposed to increase to 48.4% in 2019. The introduction of the National Biodefense Strategy in 2018, with the purpose to detect and contain biothreats at their source. The policy also aims to support and promote biomedical innovation, and improve emergency response in case of biological outbreaks. These are some of the factors contributing to the high market growth in the region.

Asia Pacific is expected to witness the highest CAGR of 9.1% over the forecast period due to surging investments in R&D. The growing significance of biodefense, and the rising threat of harmful biological materials that engender emergencies is driving the market growth. Australia and Japan are two of the most mature Asia Pacific biodefense industry as it has well-established vaccine production facilities in the country. This coupled with the presence of sophisticated healthcare infrastructure in the country contributes to its market position. Countries like India and China are rigorously expanding their R&D capabilities to cater to biological threats in the future. China is the second country after the U.S to spend the largest percentage of its GDP on R&D. These are the factors that are expected to boost the biodefense industry in the region.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10528

Competitive Landscape

The key players in the market are XOMA corporation; Altimmune Inc. Emergent Biosolutions Inc.; Dynavax Technologies Corporation; SIGA Technologies; Elusys Therapeutics Inc.; Ichor Medical Systems; Dynport Vaccine Company; Cleveland Biolabs; Bavarian Nordic; Ology Bioservices; Alnylam Pharmaceuticals Inc. among others.

Recent Developments in the Biodefense Market:

• June 2022: Emergent BioSolutions Inc. (NYSE:EBS) announced that the United States Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted).
• May 2022: Emergent BioSolutions Inc. announced that it has entered into a definitive agreement with Chimerix, Inc. to acquire Chimerix’s exclusive worldwide rights to TEMBEXA (brincidofovir), the first antiviral approved by the United States Food and Drug Administration (FDA) for all age groups for the treatment of smallpox.
• In April 2022, Heat Biologics, Inc. announced the completion of its acquisition of Elusys Therapeutics, Inc., a commercial-stage biodefense firm and developer of the anthrax therapy ANTHIM (obiltoxaximab). ANTHIM is approved for use in the United States and Canada, as well as in Europe and the United Kingdom, under the brand name Obiltoxaximab SFL.
• in January 2022, integrated Viral Protection (IVP), a Texas-based technology business, released a new portable air filtration equipment that can eliminate airborne viruses in a single pass, including sub-micron versions producing COVID-19, anthrax spores, allergens, and other dangerous respiratory triggers.

Biodefense Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Biodefense Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Biodefense Market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Biodefense Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Biodefense Market Segmentation

By Product

• Anthrax
• Botulism
• Smallpox
• Radiation/Nuclear
• Other Products

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• XOMA corporation
• Altimmune Inc.
• Emergent Biosolutions Inc.
• Dynavax Technologies Corporation.
• SIGA Technologies.
• Elusys Therapeutics Inc.
• Ichor Medical Systems.
• Dynport Vaccine Company.
• Cleveland Biolabs.
• Bavarian Nordic.

Compounding Pharmacies Market to Reach US$ 20.8 bn by 2032, driven by the increase in prevalence of chronic disease, increase in old age population and improved life expectancy: Global Insight Services

New York, February 2022: According to a new research study by Global Insight Services (GIS), the global Compounding Pharmacies Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 20.8 bn by 2032.

An Compounding Pharmacies is a type of financial institution that provides loans and other forms of financing to individuals and businesses. These platforms typically use online platforms and peer-to-peer lending models to connect borrowers with lenders. Alternative lending platforms typically have lower borrowing costs and faster funding timelines than traditional banks.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10526/

Compounding Pharmacies Market: Key Trends and Drivers

Shortage of different drugs including lifesaving drugs and other cancer medicines will boost the demand from compounding pharmacies. Some of the major factors responsible for shortages are quality and manufacturing issues. Moreover, disruption of supply chains due to the COVID-19 pandemic has also resulted in delays in the process. The postponement in raw materials supply leads to a delay in manufacturing process. This ultimately affected the supply of medication leading to its shortage. Limited capability of raw material suppliers along with long lead times and complexity of manufacturing process increases drug shortages. Drug shortages can lead to delayed or cancelled patient care and can adversely affect healthcare system revenues. Additionally, shortage of lifesaving drugs along with the unavailability of alternatives could lead to death of the patient. Therefore, capability of compounding pharmacies to critically fill the crucial gap will fuel the market expansion.

Compounding Pharmacies Market: Restraints & Challenges

The key restraints and challenges in the Compounding Pharmacies market include the stringent regulations, the need for a large amount of capital, and the lack of awareness among small businesses. The stringent regulations are the primary restraint for the growth of the Compounding Pharmacies market..

Compounding Pharmacies Market Report Findings

https://www.globalinsightservices.com/reports/compounding-pharmacies-market/

The Parenteral segment is anticipated to hold a majority of the Compounding Pharmacies Market size throughout the study period.

Based on the product, the Compounding Pharmacies market is divided into Oral, Topical, Rectal, Parenteral, Opthalmic, Nasel, and Otic. Compounding pharmacies market from parenteral segment was valued at more than USD 2 billion in 2021. Factors such as rapid absorption, faster action of the drugs, control over the dose & rate of drug administration, better bioavailability, first-pass metabolism avoidance, and reliable dosage make parenteral administration the preferred option over other routes of drug administration in emergency situations, including anaphylactic shock and cardiac arrest, as it has more predictable pharmacokinetic and pharmaco-dynamic outcomes.

The Hormone Replacement segment is anticipated to hold a majority of the Compounding Pharmacies Market size throughout the study period.

Based on the therapeutic area, the Compounding Pharmacies market is divided into Nutritional Supplements, Hormone Replacement, Dermatology, Pain Management, and Specialty Drugs. Compounding Pharmacies Market from hormone replacement segment was worth more than USD 3 billion in 2021. The surging demand for regenerative medicines for reproductive cycle boosting, thyroid hormone therapy, growth hormone replacement therapy, and anti-aging therapies, such as menopause hormone replacement, is driven by their high effectiveness, comparatively safe profile, and cost efficiency, which will positively impact the overall market.

The veterinary application segment is likely to hold a dominant Compounding Pharmacies Market share and grow at a substantial CAGR during the forecast period.

By application, the industry is bifurcated into Pediatric, Geriatric, Veterinary, and Adult. Compounding pharmacies market size from the veterinary application segment valued at over USD xx billion in 2022. Veterinarians prescribe a range of drugs from antibiotics to parasite preventatives and anti-seizure medications depending on the requirements. When none of the commercially available drugs are suitable to cater to the treatment needs of the furry patient, veterinarians opt for compounded medications to meet the specific treatment requirements. Additionally, the growing presence of veterinary clinics and increased pet adoption rates globally will fuel the segment progress.

The pharmaceutical dosage alteration (PDA) segment is anticipated to hold a majority of the Compounding Pharmacies Market size throughout the study period.

Based on, the Compounding Type is categorized into Pharmaceutical Dosage Alteration [PDA], Currently Unavailable Pharmaceutical Manufacturing [CUPM], Pharmaceutical Ingredient Alteration [PIA], and Others. The pharmaceutical dosage alteration (PDA) segment held around xx% of the market share in 2022. This segment comprises of compounding of drugs with altered dosage forms specific to the patient’s need. The alteration can be made in the drug form such as solid or liquid or it can also be in the dose. The increasing need for altered medication will boost the segment expansion.

The Hospital Pharmacy segment is anticipated to hold a majority of the Compounding Pharmacies Market size throughout the study period.

Based on distribution channel, the Compounding Pharmacies market is divided into Compounding Pharmacy, Hospital Pharmacy, and Others. The hospital pharmacy segment dominated more than 52% of the compounding pharmacies market share in 2022. The market is expanding gradually, especially owing to favorable regulatory scenarios in major economies. Thus, to take the advantage of lucrative opportunities, several hospitals are entering into the market to provide compounded medications through hospital pharmacies..

The Europe region is estimated to exhibit the highest growth rate during the Compounding Pharmacies Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The Europe compounding pharmacies market is projected to exhibit a CAGR of more than xx% over the analysis timeframe. The region may emerge as a major revenue hub owing to rising awareness regarding compounded medications, shortage of certain commercially available drugs, and the need for customized individual-focused treatments. The availability of advanced infrastructure and several government initiatives toward the development of compounding pharmacies are some other factors that will favor regional market value.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10526/

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Compounding Pharmacies market include Fagron, B. Braun, Nephron Pharmaceuticals Corporation, Fresenius Kabi, Athenex Pharma Solutions (Athenex Inc.), Dougherty’s Pharmacy, Inc., Clinigen Group PLC, Pencol Compounding Pharmacy, Lorraine’s Pharmacy, McGuff Company Inc. (McGuff Compounding Pharmacy Services), Institutional Pharmacy Solutions, Rx3 Compounding Pharmacy, Wedgewood Village Pharmacy, Inc., and Triangle Compounding Pharmacies. among others.

Recent Developments in the Compounding Pharmacies Market:

• In July 2022 Fagron acquired from Fresenius Kabi a 503B outsourcing facility in Boston. Fagron expanded its United States sterile coumpounding footprint.
• In March 2022 Fresenius Kabi acquired major stake in mAbxience which significantly enhances Fresenius Kabi’s presence in high-growth biopharmaceuticals market.

Compounding Pharmacies Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Compounding Pharmacies Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Compounding Pharmacies Market potential from 2022 to 2032 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Compounding Pharmacies Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Compounding Pharmacies Market Segmentation

By Product

• Oral
• Topical
• Rectal
• Parenteral
• Opthalmic
• Nasel
• Otic

By Therapeutic Area

• Nutritional Supplements
• Hormone Replacement
• Dermatology
• Pain Management
• Specialty Drugs
• Others

By Application

• Pediatric
• Geriatric
• Veterinary
• Adult

By Compounding Type

• Pharmaceutical Dosage Alteration [PDA]
• Currently Unavailable Pharmaceutical Manufacturing [CUPM]
• Pharmaceutical Ingredient Alteration [PIA]
• Others

By Distribution Channel

• Compounding Pharmacy
• Hospital Pharmacy
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• Fagron
• B. Braun
• Nephron Pharmaceuticals Corporation
• Fresenius Kabi
• Athenex Pharma Solutions (Athenex Inc.),
• Dougherty’s Pharmacy, Inc.
•  Clinigen Group PLC
• Pencol Compounding Pharmacy,
•  Lorraine’s Pharmacy
• McGuff Company Inc

COVID-19 Detection Kits Market to Reach US$ 2.2 Bn by 2032, driven by the government mandates requiring COVID-19 negative reports for various purposes, particularly air travel: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global COVID-19 Detection Kits Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 2.2 Billion by 2032.

The novel coronavirus is a single-stranded RNA coronavirus that resembles existing SARS-CoV and bat coronaviruses. As this spreads by close contact with an infected individual and is largely spread through respiratory droplets produced by coughing and sneezing. COVID-19 Detection Kit is a one-step real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in oropharyngeal and nasopharyngeal swab specimens, anterior nasal and mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal aspirates, as well as bronchoalveolar.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10525

COVID-19 Detection Kits Market: Key Trends and Drivers

The advent of new cutting-edge testing technologies to mitigate the adverse impact of the current pandemic is anticipated to foment the organic revenue growth of players engaged in supplying detection kits. For instance, a large-scale next-generation sequencing (NGS) technology exhibits the potential to run up to 100,000 pooled samples in a single instrument within 8 to 12 hours, which escalates the testing capacity. Although these technologies are still in the research phase, they provide lucrative opportunities for market progression in the forthcoming years.

COVID-19 Detection Kits Market: Restraints & Challenges

Some of the market obstacles include a scarcity of experienced specialists and significant investment costs, as well as legal and ethical concerns about the market methods and outcomes in numerous nations.

COVID-19 Detection Kits Market Report Findings

https://www.globalinsightservices.com/reports/covid-19-detection-kits-market/

The Immunoassay Test Strips/Cassettes segment is likely to hold a dominant COVID-19 Detection Kits Market share and grow at a substantial CAGR during the forecast period.

Based on Product, the market is bifurcated into RT-PCR Assay Kits, and Immunoassay Test Strips/Cassettes. Immunoassay test strips/ cassettes segment accounted for around xx% revenue share in 2022 and is set to register a significant CAGR through 2032. This segment is further divided into antigen test and antibody test. This is due to the rising preference towards strips/ cassettes over RT-PCR assay as they are easy to use and are rapid as well as cost-effective. These tests are used for point of care diagnosis as they show results in a couple of minutes or a few hours. Moreover, increasing new product launch and growing technological advancements in immunoassay test strips/ cassettes for virus detection will spur the market trends..

The oropharyngeal swab segment is anticipated to hold a majority of the COVID-19 Detection Kits Market size throughout the study period.

COVID-19 detection kits market based on specimen type is classified into nasopharyngeal swab, nasal swab, oropharyngeal swab, and others. The oropharyngeal swab segment surpassed USD xx billion in 2022. The swab is collected from the rear wall of the oropharynx, that is back of the throat and is inserted orally and rotated a few times for sample collection by doctors or trained professionals. This is due to the widespread availability of test swab and ease in the collection of oropharyngeal swab samples. These swabs are more comfortable and a safer method for patients who have certain critical conditions like nose bleeds or polyps. Such factors surge the demand for COVID-19 detection kits.

The hospitals segment is anticipated to hold a majority of the COVID-19 Detection Kits Market size throughout the study period.

Based on the end-use, the market is bifurcated into hospital, diagnostic laboratories and others. COVID-19 detection kits market based on end-use is classified into hospitals, diagnostic centers, and others. The hospitals segment accounted for xx% revenue share in 2022 and projected to record a lucrative CAGR in the coming years. This is driven by the increasing healthcare expenditure to provide a proper diagnosis, treatment in hospitals that increases the demand for COVID-19 detection kits. Furthermore, hospitals are well equipped with advanced medical equipment to treat patients in critical conditions and the presence of skilled professionals will further propel the industry expansion. According to the data published by the World Health Organization, in North America approximately 2,575,504 deaths were observed due to COVID-19 infection as of February 2022. Such increasing number of deaths necessitates for proper patient care in hospitals. These factors will accelerate the industry trend.

The Asia Pacific region is estimated to exhibit the highest growth rate during the COVID-19 Detection Kits Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the Asia Pacific is estimated to dominate the market with a revenue share of 36.88% in 2020. This is attributed to the continuous upsurge in coronavirus cases in Asian countries such as India, a rise in the number of diagnostic facilities, and the implementation of mass testing programs in this region. As of June 2020, Wuhan, a province of China, completed the mass testing of its 11 million individuals and ended up with 206 positive asymptomatic cases of COVID-19 in Wuhan. The supportive government initiatives also surge the demand as well as usage for COVID-19 detection kits in this region. For instance, in June 2020, the Indian Council of Medical Research, India, planned to expand the utilization of rapid antigen-based coronavirus tests instead of RT-PCR tests for more rigorous COVID-19 detection. These rapid diagnostic tests are characterized by minimal biosafety hazards and thus are widely accepted by the service providers.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10525/

Competitive Landscape

The global COVID-19 Detection Kits Market report includes players are GI, Abbott Laboratories, Qiagen, Quidel Corporation, GenMark Diagnostics, Seegene, Shenzhen Bioeasy Biotechnology, BioFire Diagnostics, Guangzhou Wondfo Biotech, F. Hoffmann-La Roche, Mylab Discovery Solutions, Randox Laboratories, Cepheid, Co-Diagnostics, SD Biosensor, and Thermo Fisher Scientific among others.

Recent Developments in the Blood-Brain Barrier Market:

• In August 2020, Kroger Health expanded its testing portfolio by launching a COVID-19 testing program for employers- COVIDCare Plus that deploys a self-administered collection method for clinical processes. This program provides a rapid, interim testing solution, and enables the company’s in-store clinics to have a testing capability of over 5,000 patients per day.
• In August 2020 as a cost-efficient and fast alternative to the conventional NP swabs. Major service providers including LabCorp and Quest Diagnostics are seeking to use this new swab type for an effective testing process.
• In August 2020, PerkinElmer, Inc. entered into a public-private partnership with the California government to provide up to 150,000 new daily tests initiating from mid-November. The partnership also focuses on the lowering of the overall cost per COVID-19 test to nearly USD 47.99. This initiative is anticipated to double the capacity of COVID-19 tests and further strengthens the market presence of Perkin Elmer in the global market
• In June 2020, the Indian Council of Medical Research, India, planned to expand the utilization of rapid antigen-based coronavirus tests instead of RT-PCR tests for more rigorous COVID-19 detection. These rapid diagnostic tests are characterized by minimal biosafety hazards and thus are widely accepted by the service providers.
• In April 2020, Novacyt, a French diagnostic company, collaborated with GlaxoSmithKline, AstraZeneca, and the University of Cambridge to increase testing for COVID-19. Under this collaboration, a new testing laboratory would set up by GlaxoSmithKline, AstraZeneca, and the University of Cambridge at the Anne McLaren laboratory of the university. The new facility uses alternative chemical reagents for kits to overcome supply shortages in the U.K..

COVID-19 Detection Kits Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global COVID-19 Detection Kits Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future COVID-19 Detection Kits Market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the COVID-19 Detection Kits Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global COVID-19 Detection Kits Market Segmentation

By Product

• RT-PCR Assay Kits
• Immunoassay Test Strips/Cassettes

By Specimen Type

• Nasopharyngeal Swab
• Oropharyngeal Swab
• Nasal Swab
• Others

By End-use

• Hospital
• Diagnostic Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• BGI
• Abbott Laboratories
• Qiagen
• Quidel Corporation
• GenMark Diagnostics
• Seegene
• Shenzhen Bioeasy Biotechnology
• BioFire Diagnostics
• Guangzhou Wondfo Biotech
• F. Hoffmann-La Roche

Vaccine Market to Reach US$ 76.9 Bn by 2032, driven by newly emerging infectious pathogenic diseases has influenced the need for effective vaccines across the globe: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Vaccine Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 76.9 Billion by 2032.

A vaccine is a biological which is used to boost the person’s immune system and help to provide immunization against chronic diseases. The suspension consists of either weakened or killed forms of disease-causing microorganisms that enhance immunity without causing diseases. The vaccine provides active immunity against a specific harmful agent such as diseases caused by a certain pathogen, injection, bacteria, virus, or parasites. By stimulating the immune system to attack the agent and eliminating these agents and increasing the life of adults and elderly individuals. After stimulation by a vaccine, B lymphocytes remain sensitized and ready to respond to the agent whenever it enters the body next time.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS20092/

Vaccine Market: Key Trends and Drivers

The expanding availability of preventive as well as therapeutic vaccines for range of diseases will boost the market expansion. Furthermore, newly emerging infectious pathogenic diseases has influenced the need for effective vaccines across the globe. This has driven the R&D activities undertaken by the operational players as well as dedicated research institutes. Advancement in vaccine development technologies to increase its efficacy and liability will offer innovative solutions to address existing disease burden. The adoption of novel development approaches including DNA/RNA vaccines, nanoparticle vaccines, and rational design will foster the vaccines market expansion.

Vaccine Market: Restraints & Challenges

Some of the market obstacles include a scarcity of experienced specialists and significant investment costs, as well as legal and ethical concerns about the market methods and outcomes in numerous nations.

Vaccine Market Report Findings

https://www.globalinsightservices.com/reports/vaccines-market/

The adult segment is likely to hold a dominant Vaccine Market share and grow at a substantial CAGR during the forecast period.

Based on age group, the market is bifurcated into S Pediatric, and Adult. Adult vaccines segment is projected to proceed at xx% CAGR during the forecast timeframe. This is attributable to increased COVID-19 vaccination rate among adults. Moreover, the awareness and improving accessibility of various preventive vaccines that helps to reduce the risk of severe infections in adults will drive the segment revenue. Additionally, some countries have established the vaccination policies and regulations for adults while travelling to particular nations to avoid the risk of disease transmission, that has further influenced the vaccination rate in adults.

The Inactivated segment is anticipated to hold a majority of the Vaccine Market size throughout the study period.

Based on the technology, the market is bifurcated into Conjugate, Live, Inactivated, Recombinant, Toxoid. Vaccines market from inactivated segment exceeded USD xx billion in 2022. This is attributed to the ability of inactivated vaccines in destruction of pathogen replication. This offers effective protection against various dreadful pathogenic diseases such as hepatitis A, influenza, polio, and rabies. Moreover, these vaccines prevent the reversal activity of pathogens to more pathogenic phenotype and avoids the interference with other functional molecules during the combination therapies. This leads to preference for inactivated technology over the live vaccines. Furthermore, as it can stored without refrigeration for certain period as the pathogen is dead, it offers ease in transportation and storage that will continue to increase its demand.

The Hepatitis segment is anticipated to hold a majority of the Vaccine Market size throughout the study period.

Based on the application, the market is bifurcated into Cancer, Hepatitis, Pneumococcal Disease, Influenza, Rotavirus, COVID-19, and others. The higher recommendation of HPV vaccination for preteens, teens as well as younger adults as it can lead to different types of cancer will enhance the industry landscape. For instance, as per the Centers for Disease Control and Prevention, each year, nearly 14 million Americans, including teens are anticipated to be infected with HPV. The vaccination also prevents the risk of cervical cancer development in women. Thus, increasing vaccination rate across the developed and developing regions to reduce further risk of severe diseases associated with HPV will stimulate the market statistics.

The Europe region is estimated to exhibit the highest growth rate during the Vaccine Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Europe vaccines market accounted for xx% revenue share in 2022. This is attributable to the adoption of new technologies and expanding awareness about the preventive vaccines in the region. The government organizations are implementing some strategies to broaden accessibility for the emerging infectious disease treatments including the COVID-19. In addition, the industry players entered in collaboration with non-government organizations to provide COVID-19 vaccines considering significantly increasing disease incidence in the region.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS20092/

Competitive Landscape

The global Vaccine Market report includes players are AstraZeneca plc., CSL Limited, Emergent BioSolutions Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Novavax, Pfizer Inc, Sanofi S.A., and Serum Institute of India, among others.

Recent Developments in the Blood-Brain Barrier Market:

• In February 2021, Ceva partnered with the French National Research Institute for Agriculture, Food, and Environment (INRAE) for R&D in the prevention of infectious diseases from animal origin and improvement of animal health.
• In January 2021, Zoetis launched the Poulvac Procerta HVT-IBD vaccine for the protection of poultry against Infectious Bursal Disease (IBD). This added to the company line of recombinant vector vaccines.
• UNICEF and Pfizer entered into a supply agreement for the COVID-19 vaccines distribution throughout 2021. This has helped the company to maintain broaden its distribution across the globe, thereby driving the business revenue.

Vaccine Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Vaccine Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Vaccine Market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Vaccine Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Vaccine Market Segmentation

By Age Group

• Pediatric
• Adult

By Technology

• Conjugated
• Live
• Inactivated
• Recombinant
• Toxoid
• Others

By Application

• Cancer
• Hepatitis
• Pneumococcal Disease
• Influenza
• COVID-19
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• AstraZeneca plc.
• CSL Limited
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc.
• Johnson & Johnson
• Merck & Co.
• Novavax
• Pfizer Inc
• Sanofi S.A.
• Serum Institute of India

Outpatient Oncology Infusion Market to Reach US$ 205.3 bn by 2032, driven by Rising prevalence of cancer along with the growing demand for outpatient infusion therapy for cancer treatment: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Outpatient Oncology Infusion Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 205.3 bn by 2032.

The outpatient oncology infusion centers offer a variety of treatments such as chemotherapy, blood transfusions, platelet transfusions, IV antibiotics, and hydration and electrolyte replacement. It also provides long-term and short infusion therapy to patients in an appropriate manner.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10523/

Outpatient Oncology Infusion Market: Key Trends and Drivers

The market is acquiring significant importance due to increasing technological advancements in infusion pumps. Additionally, the growing demand for outpatient infusion therapy for cancer treatment is anticipated to boost the market expansion. Rise in advanced technology has allowed infusion pumps to exhibit electronic health record integration such as built-in infusion and drug library of list of drugs stored in smart pump’s memory. Such advancement helps to prevent medication errors. Further, this advancement has enabled infusion system to connect to the electronic medical record by interoperability software. This provides the ability to communicate and share data accurately, effectively, and securely with different devices.

Outpatient Oncology Infusion Market: Restraints & Challenges

The key restraints and challenges in the Outpatient Oncology Infusion market include the stringent regulations, the need for a large amount of capital, high cost of treatment, and the lack of awareness among individuals regarding advanced treatment.

Outpatient Oncology Infusion Market Report Findings

https://www.globalinsightservices.com/reports/outpatient-oncology-infusion-market/

The intravenous sets segment is anticipated to hold a majority of the Outpatient Oncology Infusion Market size throughout the study period.

Based on the product, the Outpatient Oncology Infusion market is divided into Infusion Pumps, Intravenous Sets, IV Cannulas, and Needleless Connectors. Intravenous sets segment accounted for xx% revenue share in 2022 and is set to register a significant CAGR through 2032. Intravenous sets are a flexible tube that helps in smooth medication. These sets are mostly used to deliver photosensitive fluids to oncology patients and protect from light during distribution. Also, it delivers light-sensitive APIs and pharmaceutical products. Such benefits associated with this product will accelerate the industry trends.

The lung cancer segment is anticipated to hold a majority of the Outpatient Oncology Infusion Market size throughout the study period.

By application, the industry is bifurcated into Lung Cancer, Liver Cancer, Breast Cancer, and Prostate Cancer. Prostate cancer segment exceeded USD xx billion in 2022. This is owing to growing awareness among individuals regarding the prostate cancer therapy along with rising prevalence of prostate cancer. Moreover, increasing adoption of innovative infusion pump in cancer diagnosis coupled with development of targeted and immunotherapies therapies for the treatment of prostate cancer is projected to drive the business landscape.

The targeted therapy segment is likely to hold a dominant Outpatient Oncology Infusion Market share and grow at a substantial CAGR during the forecast period.

Based on therapy, the industry is categorized into Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy. Outpatient oncology infusion market from targeted therapy segment accounted for around xx% business share in 2022 and projected to record a lucrative CAGR in the coming years. Targeted therapies are utilized to specifically target cancer cells while causing no harm to the body’s normal cells. It is frequently combined with additional treatments like regular or traditional chemotherapy, radiation therapy, or staging operations. The targeted treatments aid in the treatment of cancer including multiple myeloma, prostate cancer, melanoma, lymphoma, and breast cancer. This is done by interfering with specific protein types that aid tumor development and circulation. The rate of cancer development in the body can be considerably lowered using this method.

The intramuscular (IM) segment is anticipated to hold a majority of the Outpatient Oncology Infusion Market size throughout the study period.

Based on mode, the Outpatient Oncology Infusion market is divided into Intramuscular (IM), Intravenous (IV), and Subcutaneous. The intramuscular (IM) segment is projected to witness xx% CAGR from 2022 to 2032. The intramuscular method is used to administer the majority of vaccinations. Such a method of administration lowers adverse effects at the injection site. Intramuscular injections are useful because they deliver drugs deep into muscle tissue, resulting in rapid absorption into the bloodstream.

The Asia-Pacific region is estimated to exhibit the highest growth rate during the Outpatient Oncology Infusion Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Asia Pacific outpatient oncology infusion market exceeded USD xx billion in 2022. This is primarily due to the improving outpatient healthcare facilities coupled with rising geriatric population. Such factors encourage the market players to develop innovative infusion devices to increase their quality of life. Additionally, several government initiatives are creating opportunities for market players to introduce novel infusion devices. Hence, such favorable factors are anticipated to upsurge the need for outpatient oncology infusion therapy to maintain the good health of patients, thereby fueling the regional market progression.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10523/

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Outpatient Oncology Infusion market include B. Braun Melsungen AG, Baxter, Becton, Dickinson, and Company, Fresenius Kabi, ICU Medical, Inc., IRadimed Corporation, Nipro Corporation, Terumo Corporation, Smiths Medical, Medtronic PLC, Roche Diagnostics, and Teleflex, Inc. among others.

Recent Developments in the Outpatient Oncology Infusion Market:

• In December 2021, B. Braun Medical launched the next generation OnGuard 2 CSTD. This device prevents the release of chemotherapy drug vapors and aerosols under extreme conditions. Such a product launch helped the company to enhance its product portfolio and its market position.
• In May 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS™ (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
• In September 2018, Pfizer received U.S. FDA approval for VIZIMPRO for the first line treatment for patient with EGFR-mutate metastatic non-small cell lung cancer.

Outpatient Oncology Infusion Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Outpatient Oncology Infusion Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Outpatient Oncology Infusion Market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Outpatient Oncology Infusion Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Outpatient Oncology Infusion Market Segmentation

By Product

• Infusion Pumps
• Intravenous Sets
• IV Cannulas
• Needleless Connectors

By Application

• Lung Cancer
• Liver Cancer
• Breast Cancer
• Prostate Cancer

By Threapy

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormonal Therapy

By Mode

• Intramuscular (IM)
• Intravenous (IV)
• Subcutaneous

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• B. Braun Melsungen AG
• Baxter
• Becton, Dickinson, and Company
• Fresenius Kabi
• ICU Medical, Inc
• IRadimed Corporation
• Nipro Corporation
• Terumo Corporation
• Smiths Medical
• Medtronic PLC

Neurological Biomarkers Market to Reach US$ 14.0 Bn by 2032, driven by the rise in the prevalence of neurological diseases, such as migraines, dementia, Alzheimer’s disease, brain tumors, and epilepsy: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Neurological Biomarkers market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 14.0 Billion by 2032.

Neurological Biomarkers is used to protect against the intentional interference of electronic signals. This equipment can be used to protect against radio frequency interference (RFI), electromagnetic interference (EMI), or other types of signal interference. There are a variety of anti-jamming technologies that can be used, depending on the type of interference that is being protected against. For example, RFI jamming can be countered with frequency-hopping spread spectrum (FHSS) technology, while EMI jamming can be countered with pulse-code modulation (PCM) or other digital modulation techniques.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10522/

Neurological Biomarkers Market: Key Trends and Drivers

Recent advancements in biomarkers, such as biomarker signatures are making neurological diseases more treatable. This has resulted in noninvasive testing, faster drug development, and early diagnosis. Furthermore, digital biomarkers provide various pharmaceutical companies with contextual and supplemental information to conclude clinical trial decisions. National Institute of Neurological Disorders and Stroke provides funding, such as development grants & cooperative agreements, for researchers conducting studies related to biomarker discovery, analytical validation, & clinical validation.

Neurological Biomarkers Market: Restraints & Challenges

The high cost of Neurological Biomarkers systems is likely to impede the market growth over the forecast period. However, the increment is not significant in the women population. Thus, such increase in Parkinsons disease in men aged 70 years and over is projected to supplement the market growth owing to the increase in demand for biomarkers for diagnosis.

Neurological Biomarkers Market Report Findings

https://www.globalinsightservices.com/reports/neurological-biomarker-market/

The proteomic segment is likely to hold a dominant Neurological Biomarkers market share and grow at a substantial CAGR during the forecast period.

On the basis of type, it is segmented into genomic, proteomic, metabolomic, imaging, and others. The proteomic segment accounted for the highest revenue share of over xx% in 2022. Genomic biomarkers accounted for the second-largest market share in 2022. Genomic biomarkers present promising opportunities for the development of personalized medicines and diagnostics based on an individual’s specific genetic variations & predisposition to the disease. The methods used for detecting the presence or studying genomic biomarkers for the identification of disease-associated DNA sequence variants include array Comparative Genomic Hybridization (CGH), gene expression profiling, whole-genome association studies using Single Nucleotide Polymorphisms (SNPs), and whole-genome resequencing.

The others segment is anticipated to witness significant CAGR over the forecast period due to the increasing adoption of digital biomarkers in clinical trials patient selection for neurological drugs. For instance, IXICO plc – a digital technology-based company, with expertise in neurosciences-is collaborating with biopharmaceutical companies to validate clinically digital biomarkers and use them in clinical trials.

The alzheimer disease segment is anticipated to hold a majority of the Neurological Biomarkers market size throughout the study period.

By application, the industry is classified into alzheimer disease, parkinson disease, multiple sclerosis, autism spectrum disorder, and others. The Alzheimer disease application segment accounted for the largest market share of over xx% in 2022 and is expected to remain dominant during the forecast period. This growth is credited to the high disease burden and availability of products for clinical use, such as imaging biomarkers-amyloid PET tracers for diagnosis. Furthermore, the government and non-profit organizations are providing a plethora of research opportunities that may fuel market growth. The Alzheimer Association in collaboration with The Michael J. Fox Foundation for Parkinson Research (MJFF), Alzheimer Research U.K., and the Weston Brain Institute, introduced Biomarkers Across Neurodegenerative Diseases (BAND) that provide research funding for biomarker discovery.

The Parkinson disease application segment is expected to grow at a CAGR of xx% during the forecast period owing to the growing prevalence of the disease and an increasing number of clinical trials for the disease drugs. According to the Parkinson Foundation, around 60,000 people are diagnosed with Parkinson’s disease each year in the U.S. and over 930,000 people were suffering from the disease in 2020. Several ground-breaking research trials are being conducted for improved diagnostics of Parkinson disease. Earlier, protein biomarkers, amino acids, and dopamine metabolites were the prime analytical tools for diagnosing the disease. However, several novel candidates are under investigation for potential diagnostic biomarker.

The Hospital segment is anticipated to hold a majority of the Neurological Biomarkers market size throughout the study period.

By end-use, neurological biomarkers market has been segmented into hospital & hospital laboratories, independent clinical diagnostic centers, research organizations and others. The hospital & hospital laboratories segment accounted for the largest market share of over xx% in 2022. The segment is expected to remain dominant even during the forecast period due to a rise in hospitalization. Furthermore, the ongoing development of healthcare infrastructure is anticipated to enhance the existing hospital facilities. Most of the blood-based biomarker assays are purchased by hospitals and are used in significant volumes. The research organizations & others segment is expected to grow at the fastest CAGR xx% over the forecast years owing to the increased adoption of biomarkers by pharmaceutical companies and Ambulatory Surgery Centers (ASCs) for drug discovery & development.

The North America region is estimated to exhibit the highest growth rate during the Neurological Biomarkers market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the highest market share of over xx% in 2022 and is expected to witness a significant growth rate over the forecast period. The significantly high disease burden, acceptance of biomarkers for diagnostic, drug development & prognostic purposes, and increase in research funding are some key factors contributing to the dominance of the region. Moreover, the increasing product launches along with the rise in demand for biomarkers are expected to have a positive impact on the regional market. Asia Pacific is expected to grow at the fastest CAGR of xx% from 2022 to 2032. An increasing number of clinical trials being conducted in developing countries, such as India and China, rising disease burden, and growing need for targeted drugs in the central nervous system are factors expected to drive the regional market growth.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10522/

Competitive Landscape

The key players in the Beckman Coulter Inc. (Danaher Corporation), Biolog Inc.,, BioMerieux SA,, Bruker Corporation, Charles River Laboratories International Inc,, Eurofins Scientific SE, Liofilchem S.r.l, Merck KGaA, Shimadzu Corporation, Thermo Fisher Scientific Inc., VWR International LLC., Wickham Micro Limited, among others.

Recent Developments in the Neurological Biomarkers Market:

• In May 2020, PerkinElmer launched of new products based on the HTRF technology. The product application includes biomarkers assays, biochemical cytokine-receptor binding assays, and other applications.
• In March 2020, Thermo Fisher Scientific initiated the procedure for the acquisition of QIAGEN N.V. as a part of the business strategy. This transaction values QIAGEN at about US$ 11.5 billion as per the current exchange rates. It includes the consideration of about US$ 1.4 billion of net debt.
• In December 2019, Quest Diagnostics Incorporated acquired specific assets of Boston Clinical Laboratories related to clinical laboratory services business. Boston Clinical Laboratories is a Waltham-based regional provider of laboratory services.
• In July 2019, Quest Diagnostics Incorporated entered into a partnership with Catholic Health Services (CHS). CHS is an integrated health care delivery system that accounts for about a 24% market share on Long Island. Through this partnership, the company will be able to provide laboratory and supply chain expertise, other testing-related services.
• In April 2019, PerkinElmer Inc. acquired Cisbio Bioassays. Cisbio Bioassays has developed its proprietary HTRF technology, a TR-FRET assay platform that has application in Life Sciences. The extension of Cisbio has enabled life science researchers to have access to assay tools for various target types and biological configurations, small molecule, and biologic drug discovery procedures.

Neurological Biomarkers Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Neurological Biomarkers market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Neurological Biomarkers market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Neurological Biomarkers market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Neurological Biomarkers Market Segmentation

By Type

• Genomic
• Proteomic
• Metabolomic
• Imaging
• Others

By Application

• Alzheimer’s Disease
• Parkinson’s Disease
• Multiple Sclerosis
• Autism Spectrum Disorder
• Others

By End-user

• Hospital & Hospital Laboratories
• Independent Clinical Diagnostic Centers
• Research Organizations
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• Abbott Laboratories
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Banyan Biomarkers, Inc.
• Myriad Genetics, Inc.
• DiaGenic ASA
• Quanterix

Microbial Identification Market to Reach US$ 14.0 Bn by 2032, driven by the increase in the number of military attacks in the province: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Microbial Identification market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 14.0 Billion by 2032.

Microbial Identification is used to protect against the intentional interference of electronic signals. This equipment can be used to protect against radio frequency interference (RFI), electromagnetic interference (EMI), or other types of signal interference. There are a variety of anti-jamming technologies that can be used, depending on the type of interference that is being protected against. For example, RFI jamming can be countered with frequency-hopping spread spectrum (FHSS) technology, while EMI jamming can be countered with pulse-code modulation (PCM) or other digital modulation techniques.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10521/

Microbial Identification Market: Key Trends and Drivers

The rising prevalence of infectious diseases caused by microorganisms is increasing the need for microbial identification tests across the globe. The classification of microorganisms and microbes plays a vital role in disease analysis and providing appropriate treatment. In addition, the study of bacteria, parasites, fungi, and microbes is encouraging investors in the pharmaceutical industry to finance innovation in drug development. This represents another factor positively influencing the market. Apart from this, the increasing food safety concerns around the world are driving the need for microbial identification techniques to identify food spoilage contaminants. These techniques help retain the authenticity and flavor of processed food products and increase their shelf life. Furthermore, continuous advancements in the field of microbiology and microbial identification equipment are creating a positive market outlook. Moreover, various initiatives undertaken by governments of various countries to prevent the spread of infectious diseases, coupled with the increasing expenditure on the healthcare industry, are anticipated to propel the market growth.

Microbial Identification Market: Restraints & Challenges

However, the high cost of automated microbial identification systems is likely to impede the market growth over the forecast period. Also, the high cost of automated microbial identification systems is likely to impede the market growth over the forecast period.

Microbial Identification Market Report Findings

https://www.globalinsightservices.com/reports/microbial-identification-market/

The Instruments segment is likely to hold a dominant Microbial Identification market share and grow at a substantial CAGR during the forecast period.

On the basis of Product & Service, it is segmented into Instruments, Consumables, and Services. The instruments segments are also reported to show a constant growth rate over the forecast period owing to the rising awareness among the general population about healthcare and the increasing rate of surgical procedures. For instance, in September 2019, Guthrie, a U.S.-based integrated health care system, deployed Wolters Kluwer’s POC Advisor for the detection and treatment of sepsis at four area hospitals.

The Phenotypic Methods segment is anticipated to hold a majority of the Microbial Identification market size throughout the study period.

By Method, the industry is classified into Phenotypic Methods, Genotypic Methods, Proteomics-based Methods. Among these Phenotypic Methods segment accounted for USD xx Million in 2021. Phenotypic Methods of Classifying and Identifying Microorganisms. Classification seeks to describe the diversity of bacterial species by naming and grouping organisms based on similarities. Phenotypic methods offer an advantage over genotypic methods in that they can identify a wide range of taxa, detect the resistance currently expressed, and resist genetic variability in resistance detection. Conventional phenotypic identification may involve a number of methods, including observation of growth and colony morphology on various media, analysis of manual biochemical reactions, and the use of automated and nonautomated commercially available biochemical panels.

The food and beverage testing segment is anticipated to hold a majority of the Microbial Identification market size throughout the study period.

By application, microbial identification market has been segmented into diagnostics, food and beverage testing, pharmaceuticals, cosmetics and personal care products testing, others. During the forecast period, the food and beverage testing segment is expected to grow at the fastest CAGR of xx% in the Microbial Identification Market. Accurate microbiological testing technology is vital for the detection of foodborne pathogens, possible food spoilage organisms and technological strains. Rapid identification/confirmation and strain typing methods enable food and beverage manufacturers to make fast quality and safety decisions.

The North America region is estimated to exhibit the highest growth rate during the Microbial Identification market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to dominate the microbial identification market over the forecast period owing to the factors such as the rising burden of infectious diseases and outbreaks of epidemics, growing healthcare expenditure, and the presence of well-established healthcare infrastructure. The increasing prevalence of infectious diseases in the region is the key factor fuelling the market growth. For instance, As per the data published by the Centers for Medicare & Medicaid Services, in March 2022, titled “CMS Office of the Actuary Releases 2021-2030 Projections of National Health Expenditures”, it has been observed that the annual growth in national health spending is expected to be average 5.1% over 2021-2030. Also, the National Health Spending in 2020 was USD 4.1 trillion and it is projected to reach USD 6.8 trillion by 2030. Thus, the increasing healthcare spending is expected to increase company activities and government initiatives in developing technologically advanced testing products and equipment, thereby propelling the market growth..

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10521/

Competitive Landscape

The key players in the Beckman Coulter Inc. (Danaher Corporation), Biolog Inc.,, BioMerieux SA,, Bruker Corporation, Charles River Laboratories International Inc,, Eurofins Scientific SE, Liofilchem S.r.l, Merck KGaA, Shimadzu Corporation, Thermo Fisher Scientific Inc., VWR International LLC., Wickham Micro Limited, among others.

Recent Developments in the Microbial Identification Market:

• In November 2021, Collins Aerospace acquired FlightAware, a digital aviation company that operates flight tracking and data platforms. Moreover, in October 2020, the company was selected to provide anti-jam technology for manned and unmanned ground vehicles to combat.
• In October 2021, Septentrio NV partnered with ArduSimple. The company integrated its modules into evaluation kits developed by ArduSimple. These new partnerships bring triple-band RTK as a plug-and-play solution for the most popular development platforms like Arduino, STM Nucleo, Raspberry Pi, Ardupilot, and Nvidia Jetson.

Microbial Identification Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Microbial Identification market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Microbial Identification market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Microbial Identification market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Microbial Identification Market Segmentation

By Technology

• Instruments
• Consumables
• Services

By Application

• Phenotypic Methods
• Genotypic Methods
• Proteomics-based Methods

By End-user

• Diagnostics
• Food and Beverage Testing
• Pharmaceuticals
• Cosmetics and Personal Care Products Testing
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• Beckman Coulter Inc. (Danaher Corporation)
• Biolog Inc.,
• BioMerieux SA,
• Bruker Corporation
• Charles River Laboratories International Inc.
• Eurofins Scientific SE
• Liofilchem S.r.l
• Merck KGaA
• Shimadzu Corporation
• Thermo Fisher Scientific Inc.
• VWR International LLC.
• Wickham Micro Limited.

NGS-based RNA Sequencing Market to Reach US$ 21.3 Bn by 2032, driven by the advancements of in sequencing technology, increase in acceptance of NGS technology, and growth in number of partnerships & collaborations: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global NGS-based RNA Sequencing market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 21.3 Billion by 2032.

NGS-based RNA Sequencing is used to protect against the intentional interference of electronic signals. This equipment can be used to protect against radio frequency interference (RFI), electromagnetic interference (EMI), or other types of signal interference. There are a variety of anti-jamming technologies that can be used, depending on the type of interference that is being protected against. For example, RFI jamming can be countered with frequency-hopping spread spectrum (FHSS) technology, while EMI jamming can be countered with pulse-code modulation (PCM) or other digital modulation techniques.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10519

NGS-based RNA Sequencing Market: Key Trends and Drivers

Advantages offered by NGS-based RNA sequencing such as it provides a sensitive, and accurate assay of gene expressions which is increasingly the method of choice for scientists researching on the transcriptome. Moreover, RNA sequencing based on NGS captures both known and novel features. Also, it can generate both qualitative and quantitative data, saving the research time. The market is anticipated to be driven by significant factors, including an increase in cancer incidence, government research grants, and molecular biology technical developments. Moreover, contrarily, large-scale whole-genome sequencing (WGS), one of the most preferred methods in agriculture, forensics, and biofuels, is now affordable and manageable for a typical researcher by next-generation sequencing (NGS). It enables researchers to sequence thousands of genomes in a single year or to study the whole human genome in a single sequencing session.

Technological advancements in next-generation Sequencing (NGS) by top players are another factor increasing the growth of the global NGS-based RNA sequencing market. Illumina introduced its iSeq 100 System, a semiconductor sequencing technology. Sequencing by synthesis (SBS) chemistry is combined with a semiconductor chip in semiconductor sequencing technology.

NGS-based RNA Sequencing Market: Restraints & Challenges

Restraining factors for NGS in clinical microbiology include unexplained antibiotic resistance, the inability to determine which organism is causing sickness, costs, and questionable clinical utility. The high cost of sequencing is a major barrier to the adoption of NGS. The technology is still relatively new and the costs have not yet come down to a level that is affordable for many laboratories. In addition, the lack of standardization in NGS protocols means that there is no agreed upon set of best practices for data collection and analysis. This lack of standardization makes it difficult to compare results from different laboratories and makes it difficult to reproduce results. The need for skilled personnel is another challenge facing the NGS market. The technology is complex and requires a high level of technical expertise to operate. In addition, the data generated by NGS experiments can be very large and complex, making it difficult to analyze and interpret without the help of bioinformatics experts.

NGS-based RNA Sequencing Market Report Findings

https://www.globalinsightservices.com/reports/ngs-based-rna-sequencing-market/

The platforms and consumables segment is likely to hold a dominant NGS-based RNA Sequencing market share and grow at a substantial CAGR during the forecast period.

The global NGS-based RNA sequencing market based on products & services is grouped into sample preparation, platforms & consumables, services, and data analysis. In 2021, the platforms and consumables segment held the greatest market share. This expansion is due to the ongoing technological advancements in the biotech industry. The rapidly expanding availability of innovative and affordable RNA sequencing systems, including library preparation, accelerates the segment growth. In addition, the services segment is predicted to expand at a high CAGR over the projection period due to the increasing use of services like RNA isolation, library preparation, sequencing, and data analysis as part of the full sample-to-insight solutions.

The sequencing by synthesis (SBS) segment is anticipated to hold a majority of the NGS-based RNA Sequencing market size throughout the study period.

Based on technology, the global NGS-based RNA sequencing market is grouped into sequencing by synthesis, ion semiconductor sequencing, nanopore sequencing, and single-molecule real-time sequencing. The sequencing by synthesis (SBS) segment holds most of the market share. Sequencing by synthesis (SBS) is one of the widely used technology. Moreover, SBS provides robust performance and data quality; it provides unbiased coverage across the genome. Also SBS chemistry produces extremely precise sequencing using a single base extension and competitive nucleotide addition. Many top players, such as Illumina Inc. use the sequencing by synthesis (SBS) technique in their NGS systems, making it more affordable.

The De novo sequencing segment is anticipated to hold a majority of the NGS-based RNA Sequencing market size throughout the study period.

The global NGS-based RNA sequencing market is segmented on application into De novo, epigenetics, and small RNA. De novo sequencing is the process of sequencing a novel genome in the absence of an alignment table reference sequence. De novo assembly of RNA-seq data enables the study of the transcriptome, whether data are collected from a single organism or from a mixed sample, as in meta-transcriptomics investigations. NGS-based RNA sequencing in De Novo also helps clarify similar or repetitive regions for accurate de novo assembly. De novo also provides accurate data for the genome mapping of novel organisms.

The North america region is estimated to exhibit the highest growth rate during the NGS-based RNA Sequencing market forecast period.

Regionally, the global NGS-based RNA Sequencing Market has been segmented into North America, Europe, Asia Pacific, and the Rest Of The World. North America holds the leading position. The demand for early diagnosis of diseases like cancer in the region has increased as a result of the development of next-generation sequencing, which has decreased the cost of genome sequencing, a crucial stage in a gene expression study. The presence of major companies like Illumina, Thermo Fisher Scientific, and PerkinElmer and the increased focus on genome mapping projects have significantly benefited the growth of the next-generation sequencing industry in North America. According to estimates by The National Institutes of Health’s (NIH) Human Genome Research Institute (NHGRI) in March 2022, the organization supports genomic research with such generous funding. According to statistics, the United States has invested more than any other nation in genomics research over the past ten years, amounting to 35% of all public funding received globally.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10519

Competitive Landscape

The key players in the NGS-based RNA Sequencing market are Agilent Technologies, Inc., BGI Group, Eurofins Scientific SE, Genewiz, Inc. , F. Hoffman- La Roche AG, Thermo Fisher Scientific, Zymo Research Corporation, Psomagen, Inc., Hamilton Company, Qiagen N.V. among others.

Recent Developments in the NGS-based RNA Sequencing Market:

• In December 2021, Roche launched the AVENIO Edge System to advance next-generation sequencing (NGS) technologies.
• In February 2021, Stanford Medicine launched an in-house service for whole-genome sequencing. Similarly, Cerba Research announced two COVID-19 exploratory tools in January 2021, one PCR-based and the other NGS-based, to enhance research for vaccine development against infectious diseases, including COVID-19
• In January 2021, Illumina and Myriad Genetics partnered to develop a kit-based version of the myChoice companion diagnostic (CDx) test. To improve the genomic profiles of tumor samples, this method integrates NGS technology with companion diagnostics.

NGS-based RNA Sequencing Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global NGS-based RNA Sequencing market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future NGS-based RNA Sequencing market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the NGS-based RNA Sequencing market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global NGS-based RNA Sequencing Market Segmentation

By Product & Services

• Sample Preparation
• Platforms & Consumables
• Services
• Data Analysis

By Technology

• Single-Molecule Real-Time Sequencing
• Ion Semiconductor Sequencing
• Sequencing By Synthesis
• Nanopore Sequencing

By Application

•  De novo
• Epigenetics
• Small RNA

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• Agilent Technologies Inc.
• Illumina inc.
• BGI Group
• Eurofins Scientific SE
• Genewiz, Inc.
• F. Hoffman- La Roche AG
• Thermo Fisher Scientific Inc.
• Zymo Research Corporation
• Psomagen Inc.
• Hamilton Company, Qiagen N.V.

Next-generation Sequencing Market to Reach US$ 18.7 bn by 2032, driven by extensive adoption of NGS technologies in clinical diagnostics due to rapid result time and faster processing: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Next-generation Sequencing Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 18.7 bn by 2032.

Next-generation sequencing (NGS) is a type of DNA sequencing technology that is used to determine the precise order of nucleotides in a genome. NGS is also used to identify mutations, SNPs, and other variations in a genome. NGS technology has revolutionized the field of genomics by providing a more rapid and cost-effective method for sequencing genomes. NGS can sequence an entire human genome in a matter of days, whereas it would take months or years to sequence a genome using traditional methods.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10518

Next-generation Sequencing Market: Key Trends and Drivers

Growing technological developments in NGS instruments and technologies are further likely to offer significant market growth over the coming years. For instance, in January 2020, the Intelligence Advanced Research Projects Activity in the U.S. awarded a grant of USD 23 million to the Harvard University, DNA Script, and Broad Institute. The institutes are conducting collaborative research to develop a novel technology that will combine enzymatic DNA synthesis and NGS into a single instrument. To better understand the link between genetics and disease, several countries have invested in their own national population genome mapping projects. Furthermore, millions of genomes are being sequenced by government groups to progress research and discover better ways to identify and cure cancer, uncommon disorders, and other ailments. Efforts are being undertaken by the EU to improve the region large-scale genomic data with projects such as France’s French Plan for Genomic Medicine 2025 and the U.K. 100,000 Genomes Project. Such initiatives have resulted in the growth of NGS informatics services in the region.

Next-generation Sequencing Market: Restraints & Challenges

The high cost of sequencing is a major barrier to the adoption of NGS. The technology is still relatively new and the costs have not yet come down to a level that is affordable for many laboratories. In addition, the lack of standardization in NGS protocols means that there is no agreed upon set of best practices for data collection and analysis. This lack of standardization makes it difficult to compare results from different laboratories and makes it difficult to reproduce results.

The need for skilled personnel is another challenge facing the NGS market. The technology is complex and requires a high level of technical expertise to operate. In addition, the data generated by NGS experiments can be very large and complex, making it difficult to analyze and interpret without the help of bioinformatics experts.

Next-generation Sequencing Market Report Findings

https://www.globalinsightservices.com/reports/next-generation-sequencing-market/

The sequencing segment is anticipated to hold a majority of the Next-generation Sequencing Market size throughout the study period.

Based on the workflow, the Next-generation Sequencing market is divided into Pre-sequencing, Sequencing, and NGS Data Analysis. Of these, the sequencing segment held the highest market share of xx% in 2022. NGS sequencing is the most important phase of the workflow and consequently accounts for the largest share of the market. These systems can provide an accurate amount of liquid, which is important in NGS. Moreover, functions such as changing tubes and microtiter plates are also carried out by the system, which helps streamline workflow. The advantage of using a robotic liquid handling system is that it enables researchers to focus on analyzing the data rather than managing the process. For instance, Illumina’s BaseSpace Suite aids in the analysis of sequencing data and the production of findings in a short amount of time. To expand its data analytic capabilities, the company has also purchased DRAGEN Bio-IT Platform (DRAGEN) and Edico Genome. Furthermore, Genomatix and DNAnexus, provide cloud-based solutions for the interpretation and management of enormous volumes of sequencing data.

The targeted sequencing segment is anticipated to hold a majority of the Next-generation Sequencing Market size throughout the study period.

By technology, the industry is bifurcated into whole genome sequencing, whole exome sequencing, and targeted sequencing & resequencing. The targeted sequencing and resequencing segment held the highest market share of xx% in 2022. This segment is expected to witness growth in demand after the growth of whole genome sequencing, as the availability of a large amount of whole genome data will be required to be analyzed at specific gene locations and isolated genetic expressions. There are many companies in the NGS market offering targeted sequencing services. Thus, this segment is expected to grow in tandem with the WGS segment throughout the forecast period. Illumina offers targeted resequencing with its gene panel and array finder, whereas Pacific Biosciences of California’s Sequel System with its SMRT technique allows targeted sequencing and accurate detection of variants. Targeted sequencing panels are expected to remain the workhorse for cancer molecular diagnostics and are projected to become the routine part of the heme malignancies and solid tumors.

The oncology segment is likely to hold a dominant Next-generation Sequencing Market share and grow at a substantial CAGR during the forecast period.

Based on application, the industry is categorized into oncology, clinical investigation, reproductive health, hla typing/immune system monitoring, metagenomics, epidemiology & drug development, and others. The oncology segment dominated the market and accounted for the highest market share of xx% in 2022. A gradually growing prevalence of cancer warrants the use of the latest technology to enable oncologists better understand the mechanics of cancer and tumor cells and the application of NGS for DNA and RNA sequencing, epigenetics, and analyzing chromosomal abnormalities account for over three-fourths of the global sequencing data are factors responsible for high market share. Companies like Myriad, through its myRisk product, offer genetic testing to identify people who may be at higher risk of developing certain cancers in the future. In January 2021, Merus N.V.; a clinical-stage immuno-oncology company; collaborated with National Cancer Center, Japan, and Erasmus University Medical Center, Netherlands to evaluate its HER2/3-targeting bispecific antibody in solid tumors.

The academic research segment is anticipated to hold a majority of the Next-generation Sequencing Market size throughout the study period.

Based on end-user, the Next-generation Sequencing market is divided into academic research, clinical research, hospitals & clinics, pharma & biotech entities, and others. The academic research segment held the highest market share of xx% in 2022. The application of NGS solutions in research projects that are carried out in the universities and research centers can be attributed to the largest share of this segment in the market. Furthermore, scholarships offered for Ph.D. projects in NGS are anticipated to drive demand for NGS products and services, thereby resulting in lucrative growth over the forecast period. Provision of on-site bioinformatics courses that include workshops on the practical implementation of NGS sequencing and data analysis are also expected to boost revenue generated through the academic research segment in the coming years. Owing to the use of NGS in cancer research and, more specifically, in the discovery of new cancer-related genes, studying tumor heterogeneity, and identification of alterations that are contributive to tumorigenesis the segment is expected to witness significant growth through to 2028. In addition, the availability of clinical research solutions through market entities such as Illumina, Thermo Fisher Scientific Corporation, and Agilent Technologies for target enrichment and detection is anticipated to provide this segment with high growth opportunities over the forecast period.

The North America region is estimated to exhibit the highest growth rate during the Next-generation Sequencing Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the NGS market and accounted for the largest revenue share of xx% in 2022. The regional market is driven by the presence of multiple clinical laboratories that employ NGS to provide genetic testing services. Furthermore, due to the presence of high R&D investment, and the availability of a technologically advanced healthcare research framework, the development of WGS in the region is also expected to serve as a critical factor for the growth of the market in North America throughout the forecast period. In Asia Pacific, the market is estimated to grow fast over the forecast period owing to the presence of significant developments by China and Japan for technological integration of NGS methodologies, and the development of healthcare, R&D, and clinical development frameworks of emerging economies such as India and Australia have poised the Asia Pacific NGS market to witness lucrative opportunities of growth throughout the forecast period.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10518

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Next-generation Sequencing market include Agilent Technologies, Inc, BGI Group, F. Hoffmann-La Roche AG, Illumina Inc, Oxford Nanopore Technologies, Cepheid, PerkinElmer, Inc., Eurofins Scientific, Qiagen N.V., and Thermo Fisher Scientific Inc. among others..

Recent Developments in the Next-generation Sequencing Market:

• In March 2021, Integrated DNA Technologies (IDT) announced the acquisition of Swift Biosciences, a pioneer in the development of NGS library preparation genomics kits for clinical, translational, and academic research
• In January 2021, Cerba Research announced the launch of its new tools to enhance R&D for vaccine development against infectious diseases, including COVID-19.
• In August 2020, Pediatrix Medical Group, GeneDx Inc., and OPKO Health signed an agreement to provide state-of-the-art, next-generation gene-sequencing to enhance clinical diagnosis in uncommon disorders for newborn intensive care unit.

Next-generation Sequencing Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Next-generation Sequencing Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Next-generation Sequencing Market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Next-generation Sequencing Market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Next-generation Sequencing Market Segmentation

By Workflow

• Pre-sequencing
• Sequencing
• NGS Data Analysis

By Technology

• WGS
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing

By Application

• Oncology
• Clinical Investigation
• Reproductive Health
• HLA Typing/Immune System Monitoring
• Metagenomics, Epidemiology & Drug Development
• Others

By End-user

• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharma & Biotech Entities
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of World
  • Latin America
  • Middle East
  • Africa

Key Players

• Agilent Technologies, Inc
• BGI Group
• F. Hoffmann-La Roche AG
• Illumina Inc
• Oxford Nanopore Technologies
• Cepheid
• PerkinElmer, Inc.
• Eurofins Scientific
• Qiagen N.V.
• Thermo Fisher Scientific Inc.